WO2009034029A2 - Nouveaux composés - Google Patents
Nouveaux composés Download PDFInfo
- Publication number
- WO2009034029A2 WO2009034029A2 PCT/EP2008/061771 EP2008061771W WO2009034029A2 WO 2009034029 A2 WO2009034029 A2 WO 2009034029A2 EP 2008061771 W EP2008061771 W EP 2008061771W WO 2009034029 A2 WO2009034029 A2 WO 2009034029A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- group
- substituted
- fluorine atoms
- substituents
- Prior art date
Links
- 229940127597 CGRP antagonist Drugs 0.000 title abstract description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 130
- 150000001875 compounds Chemical class 0.000 claims abstract description 122
- 239000000203 mixture Substances 0.000 claims abstract description 119
- 238000000034 method Methods 0.000 claims abstract description 117
- 150000004677 hydrates Chemical class 0.000 claims abstract description 76
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract description 42
- 150000007524 organic acids Chemical class 0.000 claims abstract description 41
- 235000005985 organic acids Nutrition 0.000 claims abstract description 41
- 150000007522 mineralic acids Chemical class 0.000 claims abstract description 40
- 239000003814 drug Substances 0.000 claims abstract description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 192
- 125000001153 fluoro group Chemical group F* 0.000 claims description 137
- 125000001424 substituent group Chemical group 0.000 claims description 118
- 150000003254 radicals Chemical class 0.000 claims description 101
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 92
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 81
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 68
- 125000000623 heterocyclic group Chemical group 0.000 claims description 60
- 229910052739 hydrogen Inorganic materials 0.000 claims description 57
- 125000001072 heteroaryl group Chemical group 0.000 claims description 53
- 125000003118 aryl group Chemical group 0.000 claims description 52
- 229910052736 halogen Inorganic materials 0.000 claims description 51
- 229910052799 carbon Inorganic materials 0.000 claims description 43
- 150000002367 halogens Chemical class 0.000 claims description 41
- 229910052757 nitrogen Inorganic materials 0.000 claims description 41
- 229910052731 fluorine Inorganic materials 0.000 claims description 35
- 125000004432 carbon atom Chemical group C* 0.000 claims description 34
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 31
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 30
- 229910052801 chlorine Inorganic materials 0.000 claims description 23
- 125000002947 alkylene group Chemical group 0.000 claims description 22
- 229910052794 bromium Inorganic materials 0.000 claims description 21
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 20
- 238000002360 preparation method Methods 0.000 claims description 19
- 125000002757 morpholinyl group Chemical group 0.000 claims description 18
- 125000004193 piperazinyl group Chemical group 0.000 claims description 18
- 125000003386 piperidinyl group Chemical group 0.000 claims description 18
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 18
- 125000002393 azetidinyl group Chemical group 0.000 claims description 16
- 229920006395 saturated elastomer Polymers 0.000 claims description 13
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 12
- 125000005843 halogen group Chemical group 0.000 claims description 12
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 11
- 125000005647 linker group Chemical group 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 125000000304 alkynyl group Chemical group 0.000 claims description 10
- 125000004429 atom Chemical group 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 9
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims description 9
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 9
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims description 9
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 9
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 8
- 125000003342 alkenyl group Chemical group 0.000 claims description 8
- 125000000532 dioxanyl group Chemical group 0.000 claims description 8
- 239000011737 fluorine Substances 0.000 claims description 8
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 8
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 8
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims description 8
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 7
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 7
- 230000002829 reductive effect Effects 0.000 claims description 7
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims description 7
- YHIIJNLSGULWAA-UHFFFAOYSA-N 1,4-thiazinane 1-oxide Chemical compound O=S1CCNCC1 YHIIJNLSGULWAA-UHFFFAOYSA-N 0.000 claims description 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 6
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 6
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 6
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 6
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000000969 carrier Substances 0.000 claims description 6
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 6
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 6
- 125000001624 naphthyl group Chemical group 0.000 claims description 6
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 6
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 6
- 125000001544 thienyl group Chemical group 0.000 claims description 6
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims description 5
- 230000001154 acute effect Effects 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 230000002757 inflammatory effect Effects 0.000 claims description 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 4
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims description 4
- 208000019695 Migraine disease Diseases 0.000 claims description 4
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 claims description 4
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 229940088597 hormone Drugs 0.000 claims description 4
- 239000005556 hormone Substances 0.000 claims description 4
- 125000002632 imidazolidinyl group Chemical group 0.000 claims description 4
- 125000002636 imidazolinyl group Chemical group 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 206010027599 migraine Diseases 0.000 claims description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 4
- 125000005968 oxazolinyl group Chemical group 0.000 claims description 4
- 125000002971 oxazolyl group Chemical group 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 4
- 125000001422 pyrrolinyl group Chemical group 0.000 claims description 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 4
- 125000005942 tetrahydropyridyl group Chemical group 0.000 claims description 4
- 125000002769 thiazolinyl group Chemical group 0.000 claims description 4
- 125000000335 thiazolyl group Chemical group 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 4
- 230000024883 vasodilation Effects 0.000 claims description 4
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims description 3
- 208000006561 Cluster Headache Diseases 0.000 claims description 3
- 206010060800 Hot flush Diseases 0.000 claims description 3
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 3
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 3
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 3
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 3
- 208000018912 cluster headache syndrome Diseases 0.000 claims description 3
- 230000002950 deficient Effects 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 229940011871 estrogen Drugs 0.000 claims description 3
- 239000000262 estrogen Substances 0.000 claims description 3
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 3
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 3
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims description 3
- 238000011321 prophylaxis Methods 0.000 claims description 3
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims description 3
- 229930192474 thiophene Natural products 0.000 claims description 3
- 150000003852 triazoles Chemical class 0.000 claims description 3
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 206010012735 Diarrhoea Diseases 0.000 claims description 2
- 206010019233 Headaches Diseases 0.000 claims description 2
- 208000012659 Joint disease Diseases 0.000 claims description 2
- 208000019693 Lung disease Diseases 0.000 claims description 2
- 208000007920 Neurogenic Inflammation Diseases 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 206010042496 Sunburn Diseases 0.000 claims description 2
- 201000010105 allergic rhinitis Diseases 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 230000017531 blood circulation Effects 0.000 claims description 2
- 231100000869 headache Toxicity 0.000 claims description 2
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 229960005181 morphine Drugs 0.000 claims description 2
- 210000002200 mouth mucosa Anatomy 0.000 claims description 2
- 230000010412 perfusion Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000003449 preventive effect Effects 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 230000035939 shock Effects 0.000 claims description 2
- 230000037380 skin damage Effects 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 208000033830 Hot Flashes Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 145
- -1 / so-propyl Chemical group 0.000 description 126
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 117
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 117
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 107
- 239000000243 solution Substances 0.000 description 105
- 239000000047 product Substances 0.000 description 103
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 99
- 238000004128 high performance liquid chromatography Methods 0.000 description 86
- 239000011541 reaction mixture Substances 0.000 description 80
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 76
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 70
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 66
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 64
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 56
- 238000006243 chemical reaction Methods 0.000 description 54
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 46
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 45
- 239000002585 base Substances 0.000 description 44
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 41
- 239000000543 intermediate Substances 0.000 description 38
- 239000002904 solvent Substances 0.000 description 38
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 33
- 239000012074 organic phase Substances 0.000 description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 31
- 235000019439 ethyl acetate Nutrition 0.000 description 30
- 239000013543 active substance Substances 0.000 description 29
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 26
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 25
- 239000001257 hydrogen Substances 0.000 description 25
- 239000007787 solid Substances 0.000 description 25
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 22
- 239000000460 chlorine Substances 0.000 description 22
- 229940093915 gynecological organic acid Drugs 0.000 description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 21
- 239000002253 acid Substances 0.000 description 21
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 21
- 230000000875 corresponding effect Effects 0.000 description 21
- 125000004093 cyano group Chemical group *C#N 0.000 description 21
- 0 C*C(C(C(C)=C)N)N Chemical compound C*C(C(C(C)=C)N)N 0.000 description 20
- 239000000741 silica gel Substances 0.000 description 20
- 229910002027 silica gel Inorganic materials 0.000 description 20
- 239000012298 atmosphere Substances 0.000 description 19
- 239000012442 inert solvent Substances 0.000 description 19
- 239000008215 water for injection Substances 0.000 description 19
- 238000001816 cooling Methods 0.000 description 18
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 18
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 17
- 239000004480 active ingredient Substances 0.000 description 17
- 229910052938 sodium sulfate Inorganic materials 0.000 description 17
- 235000011152 sodium sulphate Nutrition 0.000 description 17
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 239000003054 catalyst Substances 0.000 description 14
- 230000008878 coupling Effects 0.000 description 14
- 238000010168 coupling process Methods 0.000 description 14
- 238000005859 coupling reaction Methods 0.000 description 14
- 238000010992 reflux Methods 0.000 description 14
- 150000001412 amines Chemical class 0.000 description 13
- 239000008346 aqueous phase Substances 0.000 description 13
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 13
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 12
- 239000003826 tablet Substances 0.000 description 12
- 150000001721 carbon Chemical group 0.000 description 11
- 108010037444 diisopropylglutathione ester Proteins 0.000 description 11
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 11
- 239000012265 solid product Substances 0.000 description 11
- DDGPTROUIFVZDF-UHFFFAOYSA-N 4-(4-methyl-2-oxo-3H-1,3-benzoxazol-6-yl)-4-oxobutanoic acid Chemical compound CC1=CC(=CC2=C1NC(O2)=O)C(CCC(=O)O)=O DDGPTROUIFVZDF-UHFFFAOYSA-N 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 239000002775 capsule Substances 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 238000010438 heat treatment Methods 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- ASSKVPFEZFQQNQ-UHFFFAOYSA-N 2-benzoxazolinone Chemical compound C1=CC=C2OC(O)=NC2=C1 ASSKVPFEZFQQNQ-UHFFFAOYSA-N 0.000 description 9
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 9
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 9
- 235000019253 formic acid Nutrition 0.000 description 9
- 125000006239 protecting group Chemical group 0.000 description 9
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 108091006905 Human Serum Albumin Proteins 0.000 description 8
- 102000008100 Human Serum Albumin Human genes 0.000 description 8
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 8
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- 235000019359 magnesium stearate Nutrition 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- 229960000583 acetic acid Drugs 0.000 description 7
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 7
- 235000015165 citric acid Nutrition 0.000 description 7
- 239000005457 ice water Substances 0.000 description 7
- PWBQQBYVZKTMOV-UHFFFAOYSA-N methyl 3,4-diamino-5-methylbenzoate Chemical compound COC(=O)C1=CC(C)=C(N)C(N)=C1 PWBQQBYVZKTMOV-UHFFFAOYSA-N 0.000 description 7
- 229940044551 receptor antagonist Drugs 0.000 description 7
- 239000002464 receptor antagonist Substances 0.000 description 7
- 238000002390 rotary evaporation Methods 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- USOSUQZREODCRK-UHFFFAOYSA-N 3-piperidin-4-yl-4,5-dihydro-1h-1,3-benzodiazepin-2-one Chemical compound O=C1NC2=CC=CC=C2CCN1C1CCNCC1 USOSUQZREODCRK-UHFFFAOYSA-N 0.000 description 6
- UWAPPEQLRPVOMB-UHFFFAOYSA-N 4-methyl-2-oxo-3h-1,3-benzoxazole-6-carboxylic acid Chemical compound CC1=CC(C(O)=O)=CC2=C1NC(=O)O2 UWAPPEQLRPVOMB-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 6
- 102100025588 Calcitonin gene-related peptide 1 Human genes 0.000 description 6
- 229920002261 Corn starch Polymers 0.000 description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 6
- 239000008120 corn starch Substances 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 235000011181 potassium carbonates Nutrition 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 238000002953 preparative HPLC Methods 0.000 description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 230000003042 antagnostic effect Effects 0.000 description 5
- 229960000686 benzalkonium chloride Drugs 0.000 description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 5
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 229910052740 iodine Inorganic materials 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
- 229920000053 polysorbate 80 Polymers 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 239000003380 propellant Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000006722 reduction reaction Methods 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 235000012222 talc Nutrition 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000010626 work up procedure Methods 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 4
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 4
- WYKXYOVKFZPNTQ-UHFFFAOYSA-N 3-[1-(2-aminoethyl)piperidin-4-yl]-4,5-dihydro-1h-1,3-benzodiazepin-2-one Chemical compound C1CN(CCN)CCC1N1C(=O)NC2=CC=CC=C2CC1 WYKXYOVKFZPNTQ-UHFFFAOYSA-N 0.000 description 4
- LOOSAEPUIIJHPP-UHFFFAOYSA-N 3-chloro-5-(2-ethylpiperidine-1-carbonyl)benzoic acid Chemical compound CCC1CCCCN1C(=O)C1=CC(Cl)=CC(C(O)=O)=C1 LOOSAEPUIIJHPP-UHFFFAOYSA-N 0.000 description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical class [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 239000007821 HATU Substances 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- 239000007868 Raney catalyst Substances 0.000 description 4
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 4
- 229910000564 Raney nickel Inorganic materials 0.000 description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 150000008065 acid anhydrides Chemical class 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 235000011114 ammonium hydroxide Nutrition 0.000 description 4
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 229940116364 hard fat Drugs 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
- 208000002551 irritable bowel syndrome Diseases 0.000 description 4
- 229960004592 isopropanol Drugs 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 201000001119 neuropathy Diseases 0.000 description 4
- 230000007823 neuropathy Effects 0.000 description 4
- 238000005897 peptide coupling reaction Methods 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 238000005191 phase separation Methods 0.000 description 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 4
- 229940068968 polysorbate 80 Drugs 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 229940014800 succinic anhydride Drugs 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- FLJKJNQTDSNBLQ-UHFFFAOYSA-N 3-methoxycarbonyl-5-[methyl(methylsulfonyl)amino]benzoic acid Chemical compound COC(=O)C1=CC(N(C)S(C)(=O)=O)=CC(C(O)=O)=C1 FLJKJNQTDSNBLQ-UHFFFAOYSA-N 0.000 description 3
- QTGYCJNEAUXQNV-UHFFFAOYSA-N 4-amino-3-methyl-5-nitrobenzoic acid Chemical compound CC1=CC(C(O)=O)=CC([N+]([O-])=O)=C1N QTGYCJNEAUXQNV-UHFFFAOYSA-N 0.000 description 3
- GDRVFDDBLLKWRI-UHFFFAOYSA-N 4H-quinolizine Chemical compound C1=CC=CN2CC=CC=C21 GDRVFDDBLLKWRI-UHFFFAOYSA-N 0.000 description 3
- HJOCCPSCGWITPT-UHFFFAOYSA-N 7-methoxy-3-piperidin-4-yl-4,5-dihydro-1h-1,3-benzodiazepin-2-one Chemical compound C1CC2=CC(OC)=CC=C2NC(=O)N1C1CCNCC1 HJOCCPSCGWITPT-UHFFFAOYSA-N 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- 102000014468 Calcitonin Gene-Related Peptide Receptors Human genes 0.000 description 3
- 108010078311 Calcitonin Gene-Related Peptide Receptors Proteins 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- JGFBQFKZKSSODQ-UHFFFAOYSA-N Isothiocyanatocyclopropane Chemical compound S=C=NC1CC1 JGFBQFKZKSSODQ-UHFFFAOYSA-N 0.000 description 3
- CJUMAFVKTCBCJK-UHFFFAOYSA-N N-benzyloxycarbonylglycine Chemical compound OC(=O)CNC(=O)OCC1=CC=CC=C1 CJUMAFVKTCBCJK-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- DNKYDHSONDSTNJ-XJVRLEFXSA-N chembl1910953 Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)N)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CN=CN1 DNKYDHSONDSTNJ-XJVRLEFXSA-N 0.000 description 3
- 125000006165 cyclic alkyl group Chemical group 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- FATAVLOOLIRUNA-UHFFFAOYSA-N formylmethyl Chemical group [CH2]C=O FATAVLOOLIRUNA-UHFFFAOYSA-N 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000010907 mechanical stirring Methods 0.000 description 3
- LBHMPMUCXVQYMR-UHFFFAOYSA-N methyl 3-chloro-5-(2-ethylpiperidine-1-carbonyl)benzoate Chemical compound CCC1CCCCN1C(=O)C1=CC(Cl)=CC(C(=O)OC)=C1 LBHMPMUCXVQYMR-UHFFFAOYSA-N 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 3
- QLZNISOPACYKOR-UHFFFAOYSA-N quinoxaline-5-carboxylic acid Chemical compound C1=CN=C2C(C(=O)O)=CC=CC2=N1 QLZNISOPACYKOR-UHFFFAOYSA-N 0.000 description 3
- 238000006268 reductive amination reaction Methods 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 150000003512 tertiary amines Chemical class 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- WELHBLLMEXKKEH-UHFFFAOYSA-N 1,3-benzoxazole-2-carbonitrile Chemical compound C1=CC=C2OC(C#N)=NC2=C1 WELHBLLMEXKKEH-UHFFFAOYSA-N 0.000 description 2
- GKNYFHHMUVSRFX-UHFFFAOYSA-N 1,3-dimethyl-2-oxoquinoxaline-6-carboxylic acid Chemical compound OC(=O)C1=CC=C2N(C)C(=O)C(C)=NC2=C1 GKNYFHHMUVSRFX-UHFFFAOYSA-N 0.000 description 2
- 125000004806 1-methylethylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- OHUCGNJZMRINKX-UHFFFAOYSA-N 1-piperidin-1-ium-4-yl-3h-imidazo[4,5-b]pyridin-4-ium-2-one;dichloride Chemical compound Cl.Cl.O=C1NC2=NC=CC=C2N1C1CCNCC1 OHUCGNJZMRINKX-UHFFFAOYSA-N 0.000 description 2
- AAPROLSGJIZKSF-UHFFFAOYSA-N 2-(5-methoxy-2-nitrophenyl)acetonitrile Chemical compound COC1=CC=C([N+]([O-])=O)C(CC#N)=C1 AAPROLSGJIZKSF-UHFFFAOYSA-N 0.000 description 2
- GTRKZCKMNXBWJM-UHFFFAOYSA-N 2-(5-methoxy-2-nitrophenyl)ethanamine Chemical compound COC1=CC=C([N+]([O-])=O)C(CCN)=C1 GTRKZCKMNXBWJM-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- REXUYBKPWIPONM-UHFFFAOYSA-N 2-bromoacetonitrile Chemical compound BrCC#N REXUYBKPWIPONM-UHFFFAOYSA-N 0.000 description 2
- VEAZBNHPJDFGHD-UHFFFAOYSA-N 3,4-dimethyl-2-oxo-1,3-benzoxazole-6-carboxylic acid Chemical compound CC1=CC(C(O)=O)=CC2=C1N(C)C(=O)O2 VEAZBNHPJDFGHD-UHFFFAOYSA-N 0.000 description 2
- NRLVRZSNYQJKTN-UHFFFAOYSA-N 3-(1-benzylpiperidin-4-yl)-7-methoxy-4,5-dihydro-1h-1,3-benzodiazepin-2-one Chemical compound C1CC2=CC(OC)=CC=C2NC(=O)N1C(CC1)CCN1CC1=CC=CC=C1 NRLVRZSNYQJKTN-UHFFFAOYSA-N 0.000 description 2
- DHEGWHJPBZDXAY-UHFFFAOYSA-N 3-(2-ethylpiperidine-1-carbonyl)-5-fluorobenzoic acid Chemical compound CCC1CCCCN1C(=O)C1=CC(F)=CC(C(O)=O)=C1 DHEGWHJPBZDXAY-UHFFFAOYSA-N 0.000 description 2
- GDMYFXSIYGCRCV-UHFFFAOYSA-N 3-[1-(2-aminoethyl)piperidin-4-yl]-7-methoxy-4,5-dihydro-1h-1,3-benzodiazepin-2-one Chemical compound C1CC2=CC(OC)=CC=C2NC(=O)N1C1CCN(CCN)CC1 GDMYFXSIYGCRCV-UHFFFAOYSA-N 0.000 description 2
- LANTXZGXVINCPP-UHFFFAOYSA-N 3-bromo-1-oxidoquinolin-1-ium Chemical compound C1=CC=C2[N+]([O-])=CC(Br)=CC2=C1 LANTXZGXVINCPP-UHFFFAOYSA-N 0.000 description 2
- KVCLQGSVAXXXDG-UHFFFAOYSA-N 3-bromo-4-nitro-1-oxidoquinolin-1-ium Chemical compound C1=CC=C2C([N+](=O)[O-])=C(Br)C=[N+]([O-])C2=C1 KVCLQGSVAXXXDG-UHFFFAOYSA-N 0.000 description 2
- HLARAVKGVUMKCY-UHFFFAOYSA-N 3-chloro-5-methoxycarbonylbenzoic acid Chemical compound COC(=O)C1=CC(Cl)=CC(C(O)=O)=C1 HLARAVKGVUMKCY-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- MUEVTDYBVFUSFE-UHFFFAOYSA-N 4-(3-ethyl-4-methyl-2-oxo-1,3-benzoxazol-6-yl)-4-oxobutanoic acid Chemical compound C1=C(C(=O)CCC(O)=O)C=C2OC(=O)N(CC)C2=C1C MUEVTDYBVFUSFE-UHFFFAOYSA-N 0.000 description 2
- AHKPDUVBRLBALT-UHFFFAOYSA-N 4-amino-3-chloro-5-(diethylaminomethyl)benzoic acid Chemical compound CCN(CC)CC1=CC(C(O)=O)=CC(Cl)=C1N AHKPDUVBRLBALT-UHFFFAOYSA-N 0.000 description 2
- ZTOHIACMTGKKDU-UHFFFAOYSA-N 4-methyl-3h-1,3-benzoxazol-2-one Chemical compound CC1=CC=CC2=C1NC(=O)O2 ZTOHIACMTGKKDU-UHFFFAOYSA-N 0.000 description 2
- FKNQCJSGGFJEIZ-UHFFFAOYSA-N 4-methylpyridine Chemical compound CC1=CC=NC=C1 FKNQCJSGGFJEIZ-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 125000006847 BOC protecting group Chemical group 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- 238000005727 Friedel-Crafts reaction Methods 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 239000002841 Lewis acid Substances 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- BMHNOHQRKDVALG-UHFFFAOYSA-N NC1=CC(C(=O)OC)=CC(C)=C1NC(=O)C1CC1 Chemical compound NC1=CC(C(=O)OC)=CC(C)=C1NC(=O)C1CC1 BMHNOHQRKDVALG-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 2
- 150000008041 alkali metal carbonates Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 150000001491 aromatic compounds Chemical class 0.000 description 2
- 150000005840 aryl radicals Chemical class 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- HNTJATMUSOHLRM-UHFFFAOYSA-N benzyl 3,4-dimethyl-2-oxo-1,3-benzoxazole-6-carboxylate Chemical compound C=1C=2OC(=O)N(C)C=2C(C)=CC=1C(=O)OCC1=CC=CC=C1 HNTJATMUSOHLRM-UHFFFAOYSA-N 0.000 description 2
- KOEYZLUZAILMDG-UHFFFAOYSA-N benzyl 4-methyl-2-oxo-3h-1,3-benzoxazole-6-carboxylate Chemical compound C=1C=2OC(=O)NC=2C(C)=CC=1C(=O)OCC1=CC=CC=C1 KOEYZLUZAILMDG-UHFFFAOYSA-N 0.000 description 2
- 229910000085 borane Inorganic materials 0.000 description 2
- 230000031709 bromination Effects 0.000 description 2
- 238000005893 bromination reaction Methods 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- CHBVZDUFFACVES-UHFFFAOYSA-N dimethyl 5-(methanesulfonamido)benzene-1,3-dicarboxylate Chemical compound COC(=O)C1=CC(NS(C)(=O)=O)=CC(C(=O)OC)=C1 CHBVZDUFFACVES-UHFFFAOYSA-N 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 238000003958 fumigation Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 229940041682 inhalant solution Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 150000007517 lewis acids Chemical class 0.000 description 2
- RPNNPZHFJPXFQS-UHFFFAOYSA-N methane;rhodium Chemical compound C.[Rh] RPNNPZHFJPXFQS-UHFFFAOYSA-N 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- IMKJJEUPQOMDBC-UHFFFAOYSA-N methyl 3-(2-ethylpiperidine-1-carbonyl)-5-fluorobenzoate Chemical compound CCC1CCCCN1C(=O)C1=CC(F)=CC(C(=O)OC)=C1 IMKJJEUPQOMDBC-UHFFFAOYSA-N 0.000 description 2
- MBFHVRQPRMVUAX-UHFFFAOYSA-N methyl 4-(3-ethyl-4-methyl-2-oxo-1,3-benzoxazol-6-yl)-4-oxobutanoate Chemical compound C1=C(C(=O)CCC(=O)OC)C=C2OC(=O)N(CC)C2=C1C MBFHVRQPRMVUAX-UHFFFAOYSA-N 0.000 description 2
- WZZDVKMVGTWJIT-UHFFFAOYSA-N methyl 4-(cyclopropanecarbonylamino)-3-methyl-5-nitrobenzoate Chemical compound [O-][N+](=O)C1=CC(C(=O)OC)=CC(C)=C1NC(=O)C1CC1 WZZDVKMVGTWJIT-UHFFFAOYSA-N 0.000 description 2
- CQXAMVVAJMDYSZ-UHFFFAOYSA-N methyl 4-(cyclopropanecarbonylamino)-3-methylbenzoate Chemical compound CC1=CC(C(=O)OC)=CC=C1NC(=O)C1CC1 CQXAMVVAJMDYSZ-UHFFFAOYSA-N 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- 125000005981 pentynyl group Chemical group 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 2
- 239000011736 potassium bicarbonate Substances 0.000 description 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229960003708 sumatriptan Drugs 0.000 description 2
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 229960000257 tiotropium bromide Drugs 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- RQEUFEKYXDPUSK-SSDOTTSWSA-N (1R)-1-phenylethanamine Chemical compound C[C@@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-SSDOTTSWSA-N 0.000 description 1
- RQEUFEKYXDPUSK-ZETCQYMHSA-N (1S)-1-phenylethanamine Chemical compound C[C@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-ZETCQYMHSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- OQANPHBRHBJGNZ-FYJGNVAPSA-N (3e)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1 OQANPHBRHBJGNZ-FYJGNVAPSA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- PWLPKSIOCQNDCO-UHFFFAOYSA-N 1,2,3a,4-tetrahydro-[1,3]oxazolo[5,4-b]pyridine Chemical compound C1=CNC2OCNC2=C1 PWLPKSIOCQNDCO-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- ZHYMGSPDEVXULU-UHFFFAOYSA-N 1,2-benzodiazepin-3-one Chemical class N1=NC(=O)C=CC2=CC=CC=C21 ZHYMGSPDEVXULU-UHFFFAOYSA-N 0.000 description 1
- CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical compound C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 description 1
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 1
- JESPVWQLDNPUQU-UHFFFAOYSA-N 1,3,3a,4-tetrahydro-[1,2]oxazolo[4,3-b]pyridine Chemical compound C1=CNC2CONC2=C1 JESPVWQLDNPUQU-UHFFFAOYSA-N 0.000 description 1
- HPOQPYOUJYHQND-UHFFFAOYSA-N 1,3,4,5-tetrahydro-1,3-benzodiazepin-2-one Chemical compound N1C(=O)NCCC2=CC=CC=C21 HPOQPYOUJYHQND-UHFFFAOYSA-N 0.000 description 1
- CEMYGIWPGCOOJT-UHFFFAOYSA-N 1,3-benzodiazepin-2-one Chemical compound O=C1N=CC=C2C=CC=CC2=N1 CEMYGIWPGCOOJT-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- AICIYIDUYNFPRY-UHFFFAOYSA-N 1,3-dihydro-2H-imidazol-2-one Chemical compound O=C1NC=CN1 AICIYIDUYNFPRY-UHFFFAOYSA-N 0.000 description 1
- ILOUVJVCYDPGOA-UHFFFAOYSA-N 1-(3,4-dimethyl-2-oxo-1,3-benzoxazol-6-yl)-4-[4-(7-methoxy-2-oxo-4,5-dihydro-1h-1,3-benzodiazepin-3-yl)piperidin-1-yl]butane-1,4-dione Chemical compound C1CC2=CC(OC)=CC=C2NC(=O)N1C1CCN(C(=O)CCC(=O)C=2C=C3OC(=O)N(C)C3=C(C)C=2)CC1 ILOUVJVCYDPGOA-UHFFFAOYSA-N 0.000 description 1
- MSOBHPSKWAPPDS-UHFFFAOYSA-N 1-(4-hydroxy-3,5-dimethylphenyl)-4-[4-(2-oxo-4,5-dihydro-1h-1,3-benzodiazepin-3-yl)piperidin-1-yl]butane-1,4-dione Chemical compound CC1=C(O)C(C)=CC(C(=O)CCC(=O)N2CCC(CC2)N2C(NC3=CC=CC=C3CC2)=O)=C1 MSOBHPSKWAPPDS-UHFFFAOYSA-N 0.000 description 1
- UIFQAXFGQHOWCJ-UHFFFAOYSA-N 1-(4-methyl-2-oxo-3h-1,3-benzoxazol-6-yl)-4-[4-(2-oxo-1h-quinolin-3-yl)piperidin-1-yl]butane-1,4-dione Chemical compound C1=CC=C2NC(=O)C(C3CCN(CC3)C(=O)CCC(=O)C=3C=C(C=4NC(=O)OC=4C=3)C)=CC2=C1 UIFQAXFGQHOWCJ-UHFFFAOYSA-N 0.000 description 1
- TUPPCCBLMJJBSF-UHFFFAOYSA-N 1-[4-(7-bromo-2-oxo-4,5-dihydro-1h-1,3-benzodiazepin-3-yl)piperidin-1-yl]-4-(4-methyl-2-oxo-3h-1,3-benzoxazol-6-yl)butane-1,4-dione Chemical compound C1CC2=CC(Br)=CC=C2NC(=O)N1C(CC1)CCN1C(=O)CCC(=O)C(C=C1C)=CC2=C1NC(=O)O2 TUPPCCBLMJJBSF-UHFFFAOYSA-N 0.000 description 1
- SNQRTQDLRSHBGY-UHFFFAOYSA-N 1-[4-(7-chloro-2-oxo-4,5-dihydro-1h-1,3-benzodiazepin-3-yl)piperidin-1-yl]-4-(4-methyl-2-oxo-3h-1,3-benzoxazol-6-yl)butane-1,4-dione Chemical compound C1CC2=CC(Cl)=CC=C2NC(=O)N1C(CC1)CCN1C(=O)CCC(=O)C(C=C1C)=CC2=C1NC(=O)O2 SNQRTQDLRSHBGY-UHFFFAOYSA-N 0.000 description 1
- SKIKRKJHEDYJPL-UHFFFAOYSA-N 1-[4-(7-methoxy-2-oxo-4,5-dihydro-1h-1,3-benzodiazepin-3-yl)piperidin-1-yl]-4-(4-methyl-2-oxo-3h-1,3-benzoxazol-6-yl)butane-1,4-dione Chemical compound C1CC2=CC(OC)=CC=C2NC(=O)N1C1CCN(C(=O)CCC(=O)C=2C=C3OC(=O)NC3=C(C)C=2)CC1 SKIKRKJHEDYJPL-UHFFFAOYSA-N 0.000 description 1
- UUMUAVUQAIDFHC-UHFFFAOYSA-N 1-[4-[7-(aminomethyl)-2-oxo-4,5-dihydro-1h-1,3-benzodiazepin-3-yl]piperidin-1-yl]-4-(4-methyl-2-oxo-3h-1,3-benzoxazol-6-yl)butane-1,4-dione Chemical compound C1CC2=CC(CN)=CC=C2NC(=O)N1C(CC1)CCN1C(=O)CCC(=O)C(C=C1C)=CC2=C1NC(=O)O2 UUMUAVUQAIDFHC-UHFFFAOYSA-N 0.000 description 1
- HGPNFWNXPDTAHN-UHFFFAOYSA-N 1-benzyl-n-[2-(5-methoxy-2-nitrophenyl)ethyl]piperidin-4-amine Chemical compound COC1=CC=C([N+]([O-])=O)C(CCNC2CCN(CC=3C=CC=CC=3)CC2)=C1 HGPNFWNXPDTAHN-UHFFFAOYSA-N 0.000 description 1
- YUBDLZGUSSWQSS-UHFFFAOYSA-N 1-benzylpiperidin-4-amine Chemical compound C1CC(N)CCN1CC1=CC=CC=C1 YUBDLZGUSSWQSS-UHFFFAOYSA-N 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- NNTFPLKBXGDCPG-UHFFFAOYSA-N 1-piperidin-4-yl-3h-imidazo[4,5-b]pyridin-2-one Chemical compound O=C1NC2=NC=CC=C2N1C1CCNCC1 NNTFPLKBXGDCPG-UHFFFAOYSA-N 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- AYYNMQGCYHDBQV-UHFFFAOYSA-N 1h-pyridin-2-one;dihydrochloride Chemical compound Cl.Cl.O=C1C=CC=CN1 AYYNMQGCYHDBQV-UHFFFAOYSA-N 0.000 description 1
- 125000004825 2,2-dimethylpropylene group Chemical group [H]C([H])([H])C(C([H])([H])[H])(C([H])([H])[*:1])C([H])([H])[*:2] 0.000 description 1
- OJINISLICGANNQ-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1,2-benzoxazole Chemical compound C1=CCC2CNOC2=C1 OJINISLICGANNQ-UHFFFAOYSA-N 0.000 description 1
- HNBXASAJXOOGQD-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1,3-benzoxazole Chemical compound C1C=CC=C2OCNC21 HNBXASAJXOOGQD-UHFFFAOYSA-N 0.000 description 1
- WGSMVIHKBMAWRN-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1-benzofuran Chemical compound C1C=CC=C2OCCC21 WGSMVIHKBMAWRN-UHFFFAOYSA-N 0.000 description 1
- KELIOZMTDOSCMM-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1-benzothiophene Chemical compound C1C=CC=C2SCCC21 KELIOZMTDOSCMM-UHFFFAOYSA-N 0.000 description 1
- WJFYLCXWEXZNHU-UHFFFAOYSA-N 2,3,3a,4-tetrahydrothieno[3,2-b]pyridine Chemical compound N1C=CC=C2SCCC21 WJFYLCXWEXZNHU-UHFFFAOYSA-N 0.000 description 1
- KEQTWHPMSVAFDA-UHFFFAOYSA-N 2,3-dihydro-1h-pyrazole Chemical compound C1NNC=C1 KEQTWHPMSVAFDA-UHFFFAOYSA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- GBJFSZCDZHSAOP-UHFFFAOYSA-N 2,3-dihydroxy-4-methoxy-4-oxobutanoic acid Chemical compound COC(=O)C(O)C(O)C(O)=O GBJFSZCDZHSAOP-UHFFFAOYSA-N 0.000 description 1
- YUGDKEWUYZXXRU-UHFFFAOYSA-N 2-(4-chlorophenoxy)acetonitrile Chemical compound ClC1=CC=C(OCC#N)C=C1 YUGDKEWUYZXXRU-UHFFFAOYSA-N 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
- VVWZSYJUTIEALO-UHFFFAOYSA-N 2-[4-(2-oxo-4,5-dihydro-1h-1,3-benzodiazepin-3-yl)piperidin-1-yl]acetonitrile Chemical compound O=C1NC2=CC=CC=C2CCN1C1CCN(CC#N)CC1 VVWZSYJUTIEALO-UHFFFAOYSA-N 0.000 description 1
- YRXIMPFOTQVOHG-UHFFFAOYSA-N 2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]acetic acid Chemical compound OC(=O)CN(C)C(=O)OC(C)(C)C YRXIMPFOTQVOHG-UHFFFAOYSA-N 0.000 description 1
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- FLFGKOYMYJTXQX-UHFFFAOYSA-N 2-chloro-2-phenoxyacetonitrile Chemical compound N#CC(Cl)OC1=CC=CC=C1 FLFGKOYMYJTXQX-UHFFFAOYSA-N 0.000 description 1
- KVQJVAOMYWTLEO-UHFFFAOYSA-N 2-chlorobutanoyl chloride Chemical class CCC(Cl)C(Cl)=O KVQJVAOMYWTLEO-UHFFFAOYSA-N 0.000 description 1
- 125000003635 2-dimethylaminoethoxy group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])O* 0.000 description 1
- QBBKKFZGCDJDQK-UHFFFAOYSA-N 2-ethylpiperidine Chemical compound CCC1CCCCN1 QBBKKFZGCDJDQK-UHFFFAOYSA-N 0.000 description 1
- VGQMQYBEZDGNSS-UHFFFAOYSA-N 2-methyl-3,4-dihydro-1h-isoquinoline-7-carboxylic acid Chemical compound C1=C(C(O)=O)C=C2CN(C)CCC2=C1 VGQMQYBEZDGNSS-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- HDCLYEHDPHCZBP-UHFFFAOYSA-N 3,4-diamino-5-methylbenzoic acid Chemical compound CC1=CC(C(O)=O)=CC(N)=C1N HDCLYEHDPHCZBP-UHFFFAOYSA-N 0.000 description 1
- ADKFUVOSJFLPPM-UHFFFAOYSA-N 3,4-diamino-N-[2-[4-(7-methoxy-2-oxo-4,5-dihydro-1H-1,3-benzodiazepin-3-yl)piperidin-1-yl]-2-oxoethyl]-5-methylbenzamide Chemical compound COc1ccc2NC(=O)N(CCc2c1)C1CCN(CC1)C(=O)CNC(=O)c1cc(C)c(N)c(N)c1 ADKFUVOSJFLPPM-UHFFFAOYSA-N 0.000 description 1
- CTOUNZIAEBIWAW-UHFFFAOYSA-N 3,4-dihydro-1h-quinazolin-2-one Chemical compound C1=CC=C2NC(=O)NCC2=C1 CTOUNZIAEBIWAW-UHFFFAOYSA-N 0.000 description 1
- BOLMDIXLULGTBD-UHFFFAOYSA-N 3,4-dihydro-2h-oxazine Chemical compound C1CC=CON1 BOLMDIXLULGTBD-UHFFFAOYSA-N 0.000 description 1
- ULQRIOFGHSHNEV-UHFFFAOYSA-N 3,4-dimethyl-1,3-benzoxazol-2-one Chemical compound CC1=CC=CC2=C1N(C)C(=O)O2 ULQRIOFGHSHNEV-UHFFFAOYSA-N 0.000 description 1
- CKUFOUUWCXOLGD-UHFFFAOYSA-N 3-(1-benzylpiperidin-4-yl)-1h-imidazo[4,5-c]quinolin-2-one Chemical compound O=C1NC(C2=CC=CC=C2N=C2)=C2N1C(CC1)CCN1CC1=CC=CC=C1 CKUFOUUWCXOLGD-UHFFFAOYSA-N 0.000 description 1
- JXZZEXZZKAWDSP-UHFFFAOYSA-N 3-(2-(4-Benzamidopiperid-1-yl)ethyl)indole Chemical compound C1CN(CCC=2C3=CC=CC=C3NC=2)CCC1NC(=O)C1=CC=CC=C1 JXZZEXZZKAWDSP-UHFFFAOYSA-N 0.000 description 1
- FBMYYAKDWLNTCK-UHFFFAOYSA-N 3-[1-[4-(4-methyl-2-oxo-3h-1,3-benzoxazol-6-yl)-4-oxobutanoyl]piperidin-4-yl]-2-oxo-4,5-dihydro-1h-1,3-benzodiazepine-7-carbonitrile Chemical compound C1CC2=CC(C#N)=CC=C2NC(=O)N1C(CC1)CCN1C(=O)CCC(=O)C(C=C1C)=CC2=C1NC(=O)O2 FBMYYAKDWLNTCK-UHFFFAOYSA-N 0.000 description 1
- QZZIBMYRWBVKLM-UHFFFAOYSA-N 3-amino-4-(methylamino)benzoic acid Chemical compound CNC1=CC=C(C(O)=O)C=C1N QZZIBMYRWBVKLM-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ZGIKWINFUGEQEO-UHFFFAOYSA-N 3-bromoquinoline Chemical compound C1=CC=CC2=CC(Br)=CN=C21 ZGIKWINFUGEQEO-UHFFFAOYSA-N 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- PEIQRDFWKKDICG-UHFFFAOYSA-N 3-chloro-4-(4-methyl-1,4-diazepan-1-yl)benzonitrile Chemical compound C1CN(C)CCCN1C1=CC=C(C#N)C=C1Cl PEIQRDFWKKDICG-UHFFFAOYSA-N 0.000 description 1
- VAHXXQJJZKBZDX-UHFFFAOYSA-N 3-chloro-4-fluorobenzonitrile Chemical compound FC1=CC=C(C#N)C=C1Cl VAHXXQJJZKBZDX-UHFFFAOYSA-N 0.000 description 1
- SFUQWJIUIYAPDJ-UHFFFAOYSA-N 3-fluoro-5-methoxycarbonylbenzoic acid Chemical compound COC(=O)C1=CC(F)=CC(C(O)=O)=C1 SFUQWJIUIYAPDJ-UHFFFAOYSA-N 0.000 description 1
- ZBYIIHXWFPEVSE-UHFFFAOYSA-N 3-piperidin-4-yl-1h-imidazo[4,5-c]quinolin-2-one Chemical compound O=C1NC(C2=CC=CC=C2N=C2)=C2N1C1CCNCC1 ZBYIIHXWFPEVSE-UHFFFAOYSA-N 0.000 description 1
- CVYHGVUSBIXJAB-UHFFFAOYSA-N 4-(3,4-dimethyl-2-oxo-1,3-benzoxazol-6-yl)-4-oxobutanoic acid Chemical compound CC1=CC(C(=O)CCC(O)=O)=CC2=C1N(C)C(=O)O2 CVYHGVUSBIXJAB-UHFFFAOYSA-N 0.000 description 1
- KKCAMFSPJNWASG-UHFFFAOYSA-N 4-(4-hydroxy-3,5-dimethylphenyl)-4-oxobutanoic acid Chemical compound CC1=CC(C(=O)CCC(O)=O)=CC(C)=C1O KKCAMFSPJNWASG-UHFFFAOYSA-N 0.000 description 1
- MSTDXOZUKAQDRL-UHFFFAOYSA-N 4-Chromanone Chemical compound C1=CC=C2C(=O)CCOC2=C1 MSTDXOZUKAQDRL-UHFFFAOYSA-N 0.000 description 1
- WCQSEJSRAJSUSS-UHFFFAOYSA-N 4-acetamido-3-methylbenzoic acid Chemical compound CC(=O)NC1=CC=C(C(O)=O)C=C1C WCQSEJSRAJSUSS-UHFFFAOYSA-N 0.000 description 1
- JBAXXYICMDIMDE-UHFFFAOYSA-N 4-amino-3,5-dichloro-n-[2-oxo-2-[4-(2-oxo-4,5-dihydro-1h-1,3-benzodiazepin-3-yl)piperidin-1-yl]ethyl]benzamide Chemical compound C1=C(Cl)C(N)=C(Cl)C=C1C(=O)NCC(=O)N1CCC(N2C(NC3=CC=CC=C3CC2)=O)CC1 JBAXXYICMDIMDE-UHFFFAOYSA-N 0.000 description 1
- UHXYYTSWBYTDPD-UHFFFAOYSA-N 4-amino-3,5-dichlorobenzoic acid Chemical compound NC1=C(Cl)C=C(C(O)=O)C=C1Cl UHXYYTSWBYTDPD-UHFFFAOYSA-N 0.000 description 1
- YJWJZZKPXUFGLO-UHFFFAOYSA-N 4-amino-3-bromo-5-[(dimethylamino)methyl]benzoic acid Chemical compound CN(C)CC1=CC(C(O)=O)=CC(Br)=C1N YJWJZZKPXUFGLO-UHFFFAOYSA-N 0.000 description 1
- CDIIZULDSLKBKV-UHFFFAOYSA-N 4-chlorobutanoyl chloride Chemical compound ClCCCC(Cl)=O CDIIZULDSLKBKV-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical class OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- PCVUITKTNUPOPV-UHFFFAOYSA-N 4-methyl-2-oxo-3h-1,3-benzoxazole-6-carbaldehyde Chemical compound CC1=CC(C=O)=CC2=C1NC(=O)O2 PCVUITKTNUPOPV-UHFFFAOYSA-N 0.000 description 1
- ZFQUTAIGAQBZNO-UHFFFAOYSA-N 4-methyl-6-[4-[4-(2-oxo-1h-imidazo[4,5-c]quinolin-3-yl)piperidin-1-yl]butanoyl]-3h-1,3-benzoxazol-2-one Chemical compound C1=CC=CC2=C(NC(N3C4CCN(CC4)CCCC(=O)C=4C=C(C=5NC(=O)OC=5C=4)C)=O)C3=CN=C21 ZFQUTAIGAQBZNO-UHFFFAOYSA-N 0.000 description 1
- ICTPWBMLDZDUMU-UHFFFAOYSA-N 4-methyl-6-[4-[4-(2-oxo-3h-imidazo[4,5-b]pyridin-1-yl)piperidin-1-yl]butanoyl]-3h-1,3-benzoxazol-2-one Chemical compound C12=CC=CN=C2NC(=O)N1C(CC1)CCN1CCCC(=O)C(C=C1C)=CC2=C1NC(=O)O2 ICTPWBMLDZDUMU-UHFFFAOYSA-N 0.000 description 1
- IZHKNMRYLYTOSB-UHFFFAOYSA-N 4-methyl-6-[4-[4-(2-oxo-4,5-dihydro-1h-1,3-benzodiazepin-3-yl)piperidin-1-yl]butanoyl]-3h-1,3-benzoxazol-2-one Chemical compound C1CC2=CC=CC=C2NC(=O)N1C(CC1)CCN1CCCC(=O)C(C=C1C)=CC2=C1NC(=O)O2 IZHKNMRYLYTOSB-UHFFFAOYSA-N 0.000 description 1
- PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 description 1
- QXSSNLARLMWPIB-UHFFFAOYSA-N 5-chloro-2,3-dihydro-1,4-benzodioxine-7-carboxylic acid Chemical compound O1CCOC2=CC(C(=O)O)=CC(Cl)=C21 QXSSNLARLMWPIB-UHFFFAOYSA-N 0.000 description 1
- WVYCROBWHMAYSU-UHFFFAOYSA-N 5-phenyl-3-piperidin-1-ium-4-yl-1h-imidazol-2-one;2,2,2-trifluoroacetate Chemical compound OC(=O)C(F)(F)F.O=C1NC(C=2C=CC=CC=2)=CN1C1CCNCC1 WVYCROBWHMAYSU-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- CZRYHHRGEBEHFI-UHFFFAOYSA-N 6-[2-(dimethylamino)ethoxy]-3-piperidin-4-yl-1,4-dihydroquinazolin-2-one Chemical compound C1C2=CC(OCCN(C)C)=CC=C2NC(=O)N1C1CCNCC1 CZRYHHRGEBEHFI-UHFFFAOYSA-N 0.000 description 1
- MYYHVWCDZYVYFW-UHFFFAOYSA-N 6-[4-[4-(7-methoxy-2-oxo-4,5-dihydro-1h-1,3-benzodiazepin-3-yl)piperidin-1-yl]butanoyl]-4-methyl-3h-1,3-benzoxazol-2-one Chemical compound C1CC2=CC(OC)=CC=C2NC(=O)N1C1CCN(CCCC(=O)C=2C=C3OC(=O)NC3=C(C)C=2)CC1 MYYHVWCDZYVYFW-UHFFFAOYSA-N 0.000 description 1
- IXSGGLSJOBTONW-UHFFFAOYSA-N 7-bromo-3-piperidin-4-yl-4,5-dihydro-1h-1,3-benzodiazepin-2-one Chemical compound C1CC2=CC(Br)=CC=C2NC(=O)N1C1CCNCC1 IXSGGLSJOBTONW-UHFFFAOYSA-N 0.000 description 1
- SOWUFOLYUYNBIF-UHFFFAOYSA-N 7-chloro-3-piperidin-4-yl-4,5-dihydro-1h-1,3-benzodiazepin-2-one Chemical compound C1CC2=CC(Cl)=CC=C2NC(=O)N1C1CCNCC1 SOWUFOLYUYNBIF-UHFFFAOYSA-N 0.000 description 1
- SVWWYZONPBVZDH-UHFFFAOYSA-N 7-methyl-2-oxo-1,3-dihydrobenzimidazole-5-carboxylic acid Chemical compound CC1=CC(C(O)=O)=CC2=C1NC(=O)N2 SVWWYZONPBVZDH-UHFFFAOYSA-N 0.000 description 1
- XOGIZRHMTHEIRK-UHFFFAOYSA-N 8-(2-iodo-5-methoxyphenyl)sulfanyl-9-[3-(propan-2-ylamino)propyl]purin-6-amine Chemical compound COC1=CC=C(I)C(SC=2N(C3=NC=NC(N)=C3N=2)CCCNC(C)C)=C1 XOGIZRHMTHEIRK-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 102000001671 Acid Sensing Ion Channels Human genes 0.000 description 1
- 108010068806 Acid Sensing Ion Channels Proteins 0.000 description 1
- 102100022097 Acid-sensing ion channel 3 Human genes 0.000 description 1
- 101710099898 Acid-sensing ion channel 3 Proteins 0.000 description 1
- WKEMJKQOLOHJLZ-UHFFFAOYSA-N Almogran Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1CS(=O)(=O)N1CCCC1 WKEMJKQOLOHJLZ-UHFFFAOYSA-N 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- MNIPYSSQXLZQLJ-UHFFFAOYSA-N Biofenac Chemical compound OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl MNIPYSSQXLZQLJ-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229940122155 Bradykinin receptor antagonist Drugs 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 1
- YMCGOISGJGEPFQ-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1N(CCc(cc(cc1)Br)c1N1)C1=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1N(CCc(cc(cc1)Br)c1N1)C1=O)=O YMCGOISGJGEPFQ-UHFFFAOYSA-N 0.000 description 1
- XLYSWSQHABNDMZ-UHFFFAOYSA-N CCN(CC)Cc1cc(C(NCC(N(CC2)CCC2N(c2c(N3)nccc2)C3=O)=O)=O)cc(Cl)c1N Chemical compound CCN(CC)Cc1cc(C(NCC(N(CC2)CCC2N(c2c(N3)nccc2)C3=O)=O)=O)cc(Cl)c1N XLYSWSQHABNDMZ-UHFFFAOYSA-N 0.000 description 1
- NZCQBHCURJGDBP-UHFFFAOYSA-N Cc1c2[nH]c(C3CC3)nc2cc(C(NCC(N(CC2)CCC2N(c(cccc2)c2N2)C2=O)=O)=O)c1 Chemical compound Cc1c2[nH]c(C3CC3)nc2cc(C(NCC(N(CC2)CCC2N(c(cccc2)c2N2)C2=O)=O)=O)c1 NZCQBHCURJGDBP-UHFFFAOYSA-N 0.000 description 1
- CXLLYJFXBXUYEV-UHFFFAOYSA-N Cc1c2nc(C3CC3)[nH]c2cc(C(NCC(N(CC2)CCC2N(c2c(N3)nccc2)C3=O)=O)=O)c1 Chemical compound Cc1c2nc(C3CC3)[nH]c2cc(C(NCC(N(CC2)CCC2N(c2c(N3)nccc2)C3=O)=O)=O)c1 CXLLYJFXBXUYEV-UHFFFAOYSA-N 0.000 description 1
- JMVXUPPRVZXPBU-UHFFFAOYSA-N Cc1c2nc(N)[nH]c2cc(C(OC)=O)c1 Chemical compound Cc1c2nc(N)[nH]c2cc(C(OC)=O)c1 JMVXUPPRVZXPBU-UHFFFAOYSA-N 0.000 description 1
- FZILPSKSHSDZJG-UHFFFAOYSA-N Cc1cc(C(CCC(O)=O)=O)cc(OC2)c1NC2=O Chemical compound Cc1cc(C(CCC(O)=O)=O)cc(OC2)c1NC2=O FZILPSKSHSDZJG-UHFFFAOYSA-N 0.000 description 1
- LIPZSBZCDMIJTM-UHFFFAOYSA-N Cc1cc(C(NCC(N(CC2)CCC2N(CCc(cc(cc2)OC)c2N2)C2=O)=O)=O)cc2c1nc(N)[nH]2 Chemical compound Cc1cc(C(NCC(N(CC2)CCC2N(CCc(cc(cc2)OC)c2N2)C2=O)=O)=O)cc2c1nc(N)[nH]2 LIPZSBZCDMIJTM-UHFFFAOYSA-N 0.000 description 1
- KVSZMNMSIITIBH-UHFFFAOYSA-N Cc1cc(C(O)=O)cc2c1[nH]c(C1CC1)n2 Chemical compound Cc1cc(C(O)=O)cc2c1[nH]c(C1CC1)n2 KVSZMNMSIITIBH-UHFFFAOYSA-N 0.000 description 1
- MJLKSZKJVBRKGS-UHFFFAOYSA-N Cc1ccc(C(CCC(O)=O)=O)c(C)c1N Chemical compound Cc1ccc(C(CCC(O)=O)=O)c(C)c1N MJLKSZKJVBRKGS-UHFFFAOYSA-N 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 239000004097 EU approved flavor enhancer Substances 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229940124056 Histamine H1 receptor antagonist Drugs 0.000 description 1
- 101001032845 Homo sapiens Metabotropic glutamate receptor 5 Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 102100038357 Metabotropic glutamate receptor 5 Human genes 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 1
- UZFXMBLNHIITGE-UHFFFAOYSA-N NCC(CCC(CC1)CCC1N(CCc1ccccc1N1)C1=O)=O Chemical compound NCC(CCC(CC1)CCC1N(CCc1ccccc1N1)C1=O)=O UZFXMBLNHIITGE-UHFFFAOYSA-N 0.000 description 1
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- HOGPCCHWQKWBBC-UHFFFAOYSA-N Nc1c(cccc2)c2ncc1NC1CCN(Cc2ccccc2)CC1 Chemical compound Nc1c(cccc2)c2ncc1NC1CCN(Cc2ccccc2)CC1 HOGPCCHWQKWBBC-UHFFFAOYSA-N 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
- BNUHAJGCKIQFGE-UHFFFAOYSA-N Nitroanisol Chemical compound COC1=CC=C([N+]([O-])=O)C=C1 BNUHAJGCKIQFGE-UHFFFAOYSA-N 0.000 description 1
- OZOINGQCNVCHAE-UHFFFAOYSA-N O=C(CNC(OCc1ccccc1)=O)N(CC1)CCC1N(c1c(N2)nccc1)C2=O Chemical compound O=C(CNC(OCc1ccccc1)=O)N(CC1)CCC1N(c1c(N2)nccc1)C2=O OZOINGQCNVCHAE-UHFFFAOYSA-N 0.000 description 1
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 1
- 102100040460 P2X purinoceptor 3 Human genes 0.000 description 1
- 101710189970 P2X purinoceptor 3 Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 229940127315 Potassium Channel Openers Drugs 0.000 description 1
- 229920003080 Povidone K 25 Polymers 0.000 description 1
- 229910052777 Praseodymium Inorganic materials 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102100024448 Prostaglandin E2 receptor EP2 subtype Human genes 0.000 description 1
- 229940122144 Prostaglandin receptor antagonist Drugs 0.000 description 1
- 206010037083 Prurigo Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 102000000033 Purinergic Receptors Human genes 0.000 description 1
- 108010080192 Purinergic Receptors Proteins 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 101150084577 SST2 gene Proteins 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229940127504 Somatostatin Receptor Agonists Drugs 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000008548 Tension-Type Headache Diseases 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 229960004420 aceclofenac Drugs 0.000 description 1
- 229960004892 acemetacin Drugs 0.000 description 1
- FSQKKOOTNAMONP-UHFFFAOYSA-N acemetacin Chemical compound CC1=C(CC(=O)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FSQKKOOTNAMONP-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007960 acetonitrile Chemical class 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229960002133 almotriptan Drugs 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125684 antimigraine agent Drugs 0.000 description 1
- 239000002282 antimigraine agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- MYONAGGJKCJOBT-UHFFFAOYSA-N benzimidazol-2-one Chemical compound C1=CC=CC2=NC(=O)N=C21 MYONAGGJKCJOBT-UHFFFAOYSA-N 0.000 description 1
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940089093 botox Drugs 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000001582 butter acid Substances 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 239000003735 calcitonin gene related peptide receptor antagonist Substances 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940121376 cannabinoid receptor agonist Drugs 0.000 description 1
- 239000003537 cannabinoid receptor agonist Substances 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N carbostyril Natural products C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- UVKZSORBKUEBAZ-UHFFFAOYSA-N cyclizine Chemical compound C1CN(C)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 UVKZSORBKUEBAZ-UHFFFAOYSA-N 0.000 description 1
- 229960003564 cyclizine Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- ZOOSILUVXHVRJE-UHFFFAOYSA-N cyclopropanecarbonyl chloride Chemical compound ClC(=O)C1CC1 ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 1
- 229960004193 dextropropoxyphene Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- CRKULFPPCILKNJ-UHFFFAOYSA-N diazepan-3-one Chemical compound O=C1CCCCNN1 CRKULFPPCILKNJ-UHFFFAOYSA-N 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 description 1
- 229960004704 dihydroergotamine Drugs 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- QOWAJGMOKXVZRT-UHFFFAOYSA-N dimethyl 5-[methyl(methylsulfonyl)amino]benzene-1,3-dicarboxylate Chemical compound COC(=O)C1=CC(N(C)S(C)(=O)=O)=CC(C(=O)OC)=C1 QOWAJGMOKXVZRT-UHFFFAOYSA-N 0.000 description 1
- DEKPYXUDJRABNK-UHFFFAOYSA-N dimethyl 5-aminobenzene-1,3-dicarboxylate Chemical compound COC(=O)C1=CC(N)=CC(C(=O)OC)=C1 DEKPYXUDJRABNK-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- SLIKWVTWIGHFJE-UHFFFAOYSA-N diphenoxymethylidenecyanamide Chemical compound C=1C=CC=CC=1OC(=NC#N)OC1=CC=CC=C1 SLIKWVTWIGHFJE-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- QGBQGMHXBSLYLZ-UHFFFAOYSA-N ditert-butyl-(1-naphthalen-1-ylnaphthalen-2-yl)phosphane Chemical group C1=CC=C2C(C3=C4C=CC=CC4=CC=C3P(C(C)(C)C)C(C)(C)C)=CC=CC2=C1 QGBQGMHXBSLYLZ-UHFFFAOYSA-N 0.000 description 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
- 229960001253 domperidone Drugs 0.000 description 1
- 229960002866 duloxetine Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000773 effect on pain Effects 0.000 description 1
- PWVXXGRKLHYWKM-LJQANCHMSA-N eletriptan Chemical compound CN1CCC[C@@H]1CC(C1=C2)=CNC1=CC=C2CCS(=O)(=O)C1=CC=CC=C1 PWVXXGRKLHYWKM-LJQANCHMSA-N 0.000 description 1
- 229960002472 eletriptan Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960003133 ergot alkaloid Drugs 0.000 description 1
- OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 1
- 229960004943 ergotamine Drugs 0.000 description 1
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- NTNBNHCYSBPWGE-UHFFFAOYSA-N ethyl 2-carbonochloridoylcyclopropane-1-carboxylate Chemical compound CCOC(=O)C1CC1C(Cl)=O NTNBNHCYSBPWGE-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 229960004945 etoricoxib Drugs 0.000 description 1
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
- 229960001395 fenbufen Drugs 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- SMANXXCATUTDDT-QPJJXVBHSA-N flunarizine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 SMANXXCATUTDDT-QPJJXVBHSA-N 0.000 description 1
- 229960000326 flunarizine Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 229960002284 frovatriptan Drugs 0.000 description 1
- SIBNYOSJIXCDRI-SECBINFHSA-N frovatriptan Chemical compound C1=C(C(N)=O)[CH]C2=C(C[C@H](NC)CC3)C3=NC2=C1 SIBNYOSJIXCDRI-SECBINFHSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229910021485 fumed silica Inorganic materials 0.000 description 1
- 150000002244 furazanes Chemical class 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000003825 glutamate receptor antagonist Substances 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 239000000938 histamine H1 antagonist Substances 0.000 description 1
- 229960000443 hydrochloric acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- AQYSYJUIMQTRMV-UHFFFAOYSA-N hypofluorous acid Chemical group FO AQYSYJUIMQTRMV-UHFFFAOYSA-N 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- YAMHXTCMCPHKLN-UHFFFAOYSA-N imidazolidin-2-one Chemical compound O=C1NCCN1 YAMHXTCMCPHKLN-UHFFFAOYSA-N 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical compound C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 229960002056 indoramin Drugs 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- UEXQBEVWFZKHNB-UHFFFAOYSA-N intermediate 29 Natural products C1=CC(N)=CC=C1NC1=NC=CC=N1 UEXQBEVWFZKHNB-UHFFFAOYSA-N 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Chemical group 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- XVQUOJBERHHONY-UHFFFAOYSA-N isometheptene Chemical compound CNC(C)CCC=C(C)C XVQUOJBERHHONY-UHFFFAOYSA-N 0.000 description 1
- 229960003046 isometheptene Drugs 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- CZRQXSDBMCMPNJ-ZUIPZQNBSA-N lisinopril dihydrate Chemical compound O.O.C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 CZRQXSDBMCMPNJ-ZUIPZQNBSA-N 0.000 description 1
- WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 description 1
- 229960002202 lornoxicam Drugs 0.000 description 1
- OXROWJKCGCOJDO-JLHYYAGUSA-N lornoxicam Chemical compound O=C1C=2SC(Cl)=CC=2S(=O)(=O)N(C)\C1=C(\O)NC1=CC=CC=N1 OXROWJKCGCOJDO-JLHYYAGUSA-N 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- LRMFSMKHXKDUDG-UHFFFAOYSA-N methyl 2,1,3-benzothiadiazole-5-carboxylate Chemical compound C1=C(C(=O)OC)C=CC2=NSN=C21 LRMFSMKHXKDUDG-UHFFFAOYSA-N 0.000 description 1
- NOJYGOFJZFPKFY-UHFFFAOYSA-N methyl 4-(1,1-dioxo-1,2,6-thiadiazinan-2-yl)-3-methylbenzoate Chemical compound CC1=CC(C(=O)OC)=CC=C1N1S(=O)(=O)NCCC1 NOJYGOFJZFPKFY-UHFFFAOYSA-N 0.000 description 1
- UFZUXAPLCSSLMR-UHFFFAOYSA-N methyl 4-(3,4-diaminophenyl)-4-oxobutanoate Chemical compound COC(=O)CCC(=O)C1=CC=C(N)C(N)=C1 UFZUXAPLCSSLMR-UHFFFAOYSA-N 0.000 description 1
- YLOJERPXWHPTSB-UHFFFAOYSA-N methyl 4-(4-methyl-2-oxo-3h-1,3-benzoxazol-6-yl)-4-oxobutanoate Chemical compound COC(=O)CCC(=O)C1=CC(C)=C2NC(=O)OC2=C1 YLOJERPXWHPTSB-UHFFFAOYSA-N 0.000 description 1
- IGCBUUTXGYCQAI-UHFFFAOYSA-N methyl 4-(butanoylamino)-3-methyl-5-nitrobenzoate Chemical compound CCCC(=O)NC1=C(C)C=C(C(=O)OC)C=C1[N+]([O-])=O IGCBUUTXGYCQAI-UHFFFAOYSA-N 0.000 description 1
- ZHIPSMIKSRYZFV-UHFFFAOYSA-N methyl 4-amino-3-methylbenzoate Chemical compound COC(=O)C1=CC=C(N)C(C)=C1 ZHIPSMIKSRYZFV-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- 229940101564 micardis Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229960005127 montelukast Drugs 0.000 description 1
- MENOBBYDZHOWLE-UHFFFAOYSA-N morpholine-2,3-dione Chemical compound O=C1NCCOC1=O MENOBBYDZHOWLE-UHFFFAOYSA-N 0.000 description 1
- LTAFRIZVOKDEMU-UHFFFAOYSA-N morpholine-3-thione Chemical compound S=C1COCCN1 LTAFRIZVOKDEMU-UHFFFAOYSA-N 0.000 description 1
- DVHKACDABQUXBI-UHFFFAOYSA-N n-[2-(2-amino-5-methoxyphenyl)ethyl]-1-benzylpiperidin-4-amine Chemical compound COC1=CC=C(N)C(CCNC2CCN(CC=3C=CC=CC=3)CC2)=C1 DVHKACDABQUXBI-UHFFFAOYSA-N 0.000 description 1
- MQHQVQQBWROHAH-UHFFFAOYSA-N n-[2-[4-(7-methoxy-2-oxo-4,5-dihydro-1h-1,3-benzodiazepin-3-yl)piperidin-1-yl]-2-oxoethyl]-4-methyl-2-oxo-3h-1,3-benzoxazole-6-carboxamide Chemical compound C1CC2=CC(OC)=CC=C2NC(=O)N1C1CCN(C(=O)CNC(=O)C=2C=C3OC(=O)NC3=C(C)C=2)CC1 MQHQVQQBWROHAH-UHFFFAOYSA-N 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
- 229960004255 nadolol Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229960005254 naratriptan Drugs 0.000 description 1
- UNHGSHHVDNGCFN-UHFFFAOYSA-N naratriptan Chemical compound C=12[CH]C(CCS(=O)(=O)NC)=CC=C2N=CC=1C1CCN(C)CC1 UNHGSHHVDNGCFN-UHFFFAOYSA-N 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000004999 nitroaryl group Chemical group 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- YHYVSZZDQVQYOT-UHFFFAOYSA-N oxazepan-3-one Chemical compound O=C1CCCCON1 YHYVSZZDQVQYOT-UHFFFAOYSA-N 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 229960004662 parecoxib Drugs 0.000 description 1
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical compound O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 description 1
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 1
- 229960005235 piperonyl butoxide Drugs 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- FIADGNVRKBPQEU-UHFFFAOYSA-N pizotifen Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CCC2=C1C=CS2 FIADGNVRKBPQEU-UHFFFAOYSA-N 0.000 description 1
- 229960004572 pizotifen Drugs 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 1
- 229960001233 pregabalin Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
- 229960003111 prochlorperazine Drugs 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- YEYHFKBVNARCNE-UHFFFAOYSA-N pyrido[2,3-b]pyrazine Chemical compound N1=CC=NC2=CC=CN=C21 YEYHFKBVNARCNE-UHFFFAOYSA-N 0.000 description 1
- OHZYAOYVLLHTGW-UHFFFAOYSA-N pyrido[3,2-c]pyridazine Chemical compound C1=CN=NC2=CC=CN=C21 OHZYAOYVLLHTGW-UHFFFAOYSA-N 0.000 description 1
- BWESROVQGZSBRX-UHFFFAOYSA-N pyrido[3,2-d]pyrimidine Chemical compound C1=NC=NC2=CC=CN=C21 BWESROVQGZSBRX-UHFFFAOYSA-N 0.000 description 1
- JOZPEVMCAKXSEY-UHFFFAOYSA-N pyrimido[5,4-d]pyrimidine Chemical compound N1=CN=CC2=NC=NC=C21 JOZPEVMCAKXSEY-UHFFFAOYSA-N 0.000 description 1
- 150000003235 pyrrolidines Chemical class 0.000 description 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- 229960000425 rizatriptan Drugs 0.000 description 1
- TXHZXHICDBAVJW-UHFFFAOYSA-N rizatriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1CN1C=NC=N1 TXHZXHICDBAVJW-UHFFFAOYSA-N 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000003195 sodium channel blocking agent Substances 0.000 description 1
- 229940086766 sodium chloride 180 mg Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
- WGRULTCAYDOGQK-UHFFFAOYSA-M sodium;sodium;hydroxide Chemical compound [OH-].[Na].[Na+] WGRULTCAYDOGQK-UHFFFAOYSA-M 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- RINCXYDBBGOEEQ-UHFFFAOYSA-N succinic anhydride Chemical class O=C1CCC(=O)O1 RINCXYDBBGOEEQ-UHFFFAOYSA-N 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 1
- NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- UJJLJRQIPMGXEZ-SCSAIBSYSA-N tetrahydrofuran-2-carboxylic acid Chemical compound OC(=O)[C@H]1CCCO1 UJJLJRQIPMGXEZ-SCSAIBSYSA-N 0.000 description 1
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- DNGMYXZLJGHHOM-UHFFFAOYSA-N thiazinane 1,1-dioxide Chemical compound O=S1(=O)CCCCN1 DNGMYXZLJGHHOM-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- XSROQCDVUIHRSI-UHFFFAOYSA-N thietane Chemical compound C1CSC1 XSROQCDVUIHRSI-UHFFFAOYSA-N 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 229960004394 topiramate Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 238000005533 tritiation Methods 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- 229940102566 valproate Drugs 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 239000000085 vanilloid receptor antagonist Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- 229960005318 vigabatrin Drugs 0.000 description 1
- PJDFLNIOAUIZSL-UHFFFAOYSA-N vigabatrin Chemical compound C=CC(N)CCC(O)=O PJDFLNIOAUIZSL-UHFFFAOYSA-N 0.000 description 1
- 208000037911 visceral disease Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- 229960001360 zolmitriptan Drugs 0.000 description 1
- ULSDMUVEXKOYBU-ZDUSSCGKSA-N zolmitriptan Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1C[C@H]1COC(=O)N1 ULSDMUVEXKOYBU-ZDUSSCGKSA-N 0.000 description 1
- 229960003414 zomepirac Drugs 0.000 description 1
- ZXVNMYWKKDOREA-UHFFFAOYSA-N zomepirac Chemical compound C1=C(CC(O)=O)N(C)C(C(=O)C=2C=CC(Cl)=CC=2)=C1C ZXVNMYWKKDOREA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Definitions
- Heterocycle which is substituted on a nitrogen atom with a radical R 3 - 3 - 1 - 1 and on a carbon atom with one or two radicals R 3 - 3 - 1 - 3 , or (f) a heteroaryl group attached to a carbon atom a radical R 3 - 3 - 1 - substituted 3, (g) aryl-Ci- 3 alkyl-NH-, aryl-C 1-3 alkyl-N (C 1-3 alkyl) -,
- radical R 322 optionally in addition to a nitrogen atom by a radical R 322 may be substituted and
- a fourth embodiment of the present invention resides in the compounds of the above-mentioned conventional formulators II, IIn which are AA, XX ,, RR 22 and RR 33 'as defined above in the first, second or third embodiment and
- Substituents R 8 may be the same or different,
- R 1 is a group of the general formulas
- C (R 7 1) C (R 7 - 2) or C (R 7 / I) 2 -N ( R 7 2 ) in each case a radical R 7 1 together with an adjacent radical R 7 2 and the atoms to which these radicals are bonded, also a group selected from cyclobutyl, cyclopentyl, cyclohexyl, cyclopentenyl, cyclohexenyl,
- R 6 - 3 (a) H, halogen, C 1-6 alkyl, C 3 - 6 cycloalkyl,
- R 7 - 3 (a) halogen, Ci -6 -alkyl, C 3-6 cycloalkyl,
- Ci_3-alkyl group in which each methylene group is substituted by up to two fluorine atoms and each methyl group by up to three fluorine atoms,
- R 9 and R 10 together may also form a ring selected from among
- a sixth embodiment of the present invention consists in the compounds of the above general formula I in which A, X, R 2 and R 3 are as defined above in the first, second or third embodiment and
- R 1 is a group of the general formulas
- Ci -3 alkyl a Ci -3 alkyl, or Ci -3 alkyl-O-group wherein each methylene group with up to two fluorine atoms and each methyl group with up to three fluorine atoms is substituted,
- Ci -3 alkyl group wherein each methylene group of up to two fluorine atoms and each methyl group with up to three fluorine atoms is substituted
- R 8 - 1 is halogen, HO- or d -6- alkyl-O-,
- R 9 is (a) H
- R 3 is a group of general formula IV
- R 3 - 1 (a) H, F, Cl, Br, -NH2, d-NH- -3 alkyl, (Ci -3 alkyl) 2 N-, H 3 CC (O) -NH- H 3 CS (O) 2 -N (Ci -3 alkyl), -CN, -OH,
- R 3 - 3 - 1 - 2 (a) H, Ci- 4 alkyl, C 3 - 6 cycloalkyl, or (b) aryl-d- 3 alkylene,
- R 32 and R 33 together with the carbon atoms to which they are attached form a monounsaturated 5-membered or mono- or diunsaturated 6-membered heterocycle, an aryl or heteroaryl group, wherein
- heterocycles may contain a carbonyl, thiocarbonyl, sulfonyl or an optionally substituted by an R 32 1 substituted lmino group adjacent to a nitrogen atom, and
- radical R 322 optionally in addition to a nitrogen atom by a radical R 322 may be substituted and
- radical R '3.2.3 may be substituted, or
- Another embodiment of the present invention resides in the compounds of the above general formula I in which A, X, R 1 and R 2 are as defined above under the first, second, third, fourth, fifth, sixth, seventh, eighth or ninth embodiment are and
- R 3 is a group selected from
- a twelfth embodiment of the present invention is the compounds of the above general formula I in which A, X, R 1 and R 2 are as defined above in the first, second, third, fourth, fifth, sixth, seventh, eighth or ninth embodiment are and
- R 3 - 1 (a) H, F, Cl, Br, -NH 2 , d -3 -alkyl-NH-, H 3 CC (O) -NH-, -CN, -OH,
- a thirteenth embodiment of the present invention is the compounds of the above general formula I wherein A, X, R 1 and R 2 are as defined above in the first, second, third, fourth, fifth, sixth, seventh, eighth or ninth embodiment are and a group selected from
- R 3 - 2 - 3 - 1 (a) H, (b) CN, OH 1 -O-Ci -3 -alkyl 1 CF 3 or
- R 3 - 3 - 1 (a) R 3 - 3 - 1 - 1 R 33 1 2 N- or
- R 3 - 4 H means
- a sixteenth embodiment of the present invention consists in the compounds of the above general formula I in which A, X, R 1 and R 2 are as are defined above under the first, second, third, fourth, fifth, sixth, seventh, eighth or ninth embodiment and
- R 3 is a group selected from
- the atom of the substituent following the point of attachment is understood as the atom with the position number 1.
- C 1-3 -alkyl (including those which are part of other radicals) are branched and unbranched alkyl groups having 1 to 3 carbon atoms
- C 1-4 -alkyl are branched and unbranched alkyl groups having 1 to 4 carbon atoms
- Ci- 6 alkyl are understood to mean branched and unbranched alkyl groups having 1 to 6 carbon atoms.
- Examples include: methyl, ethyl, n-propyl, / so-propyl, n-butyl, / so-butyl, sec-butyl, te / f-butyl, pentyl, neopentyl or n-hexyl.
- the abbreviations Me, Et, n-Pr, / -Pr, n-Bu, / -Bu, t-Bu, etc. are also used for the abovementioned groups.
- the definitions of propyl and butyl include all conceivable isomeric forms of the respective radicals.
- propyl includes n-propyl and / so-propyl
- butyl includes / so-butyl, sec-butyl and te / f-butyl, etc.
- d- 6 -alkylene (including those which are part of other groups) are branched and unbranched alkylene groups with 1 to 6 carbon atoms and by the term are "C 1-3 alkylene” are meant branched and unbranched alkylene groups with 1 to 3
- propylene encompasses all conceivable isomeric forms of the respective radicals of the same carbon number.
- propyl also includes 1-methylethylene and butylene includes 1-methylpropylene, 1, 1-dimethylethylene, 1, 2-dimethylethylene.
- C 0 alkylene means a bond.
- C 2 - 6 -alkylene (including those which are part of other radicals) are branched and unbranched alkylene groups having 2 to 6 carbon atoms and the term "C 2 - 4 -alkylene” branched and unbranched alkylene groups having 2 to 4
- Understood carbon atoms examples include: ethylene, propylene, 1-methylethylene, butylene, 1-methylpropylene, 1, 1-dimethylethylene, 1, 2-dimethylethylene, pentylene, 1, 1-dimethylpropylene, 2,2, -dimethylpropylene, 1, 2 Dimethylpropylene, 1, 3-dimethylpropylene or hexylene.
- propylene, butylene, pentylene and hexylene include all conceivable isomeric forms of the respective radicals of the same carbon number.
- propylene also includes 1-methylethylene and butylene includes 1-methylpropylene, 1, 1-dimethylethylene, 1, 2-dimethylethylene.
- Cs- ⁇ -cycloalkyl (including those which are part of other radicals) are cyclic alkyl groups having 3 to 6 carbon atoms and the term "Cs-e-cycloalkyl” is understood to mean cyclic alkyl groups having 5 to 6 carbon atoms. Examples include: cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
- the cyclic alkyl groups may be substituted with one or more groups selected from the group consisting of methyl, ethyl, iso-propyl, tert-butyl, hydroxy, fluoro, chloro, bromo and iodo.
- C 3-6 -cycloalkenyl means cyclic alkylene groups having 3 to 6 carbon atoms which contain an unsaturated bond. Examples include: cyclopentenyl or cyclohexenyl. Unless otherwise stated, the cyclic alkylene groups may be substituted with one or more groups selected from the group consisting of methyl, ethyl, iso-propyl, tert-butyl, hydroxy, fluorine, chlorine, bromine and iodine.
- heterocyclyl or “heterocycle”, unless otherwise specified in the definitions, means stable 5-, 6- or 7-membered monocyclic or 8-, 9-, 10- or 11-membered bicyclic heterocyclic ring systems which in at least one ring form no aromatic ring system and in addition to carbon atoms can carry one to four heteroatoms, which are selected from the group consisting of nitrogen, oxygen and sulfur. Both nitrogen atoms and sulfur atoms can optionally be oxidized and nitrogen atoms can be quaternized.
- the heterocyclic ring may contain one or two carbonyl, thiocarbonyl or cyanimino groups adjacent to a nitrogen atom.
- the above heterocycles may be linked via a carbon atom or via a nitrogen atom with the remainder of the molecule.
- heterocycles may be substituted by one or more radicals selected from the group consisting of: (a) OH, NO 2 , CN, OCF 3 , OCHF 2 , OCH 2 F, NH 2 ,
- Examples include, but are not limited to, azetidine, oxetane, thietane, thietandioxide, tetrahydrofuran, dihydrofuran, dioxalane, imidazolidine, imidazoline, imidazolidinone, dihydroimidazolone, oxazoline, oxazolidine, oxazolidinone, pyrrolidines, dihydropyrazole, pyrrolidine, pyrroline , Morpholine, tetrahydropyridine, dihydropyran, tetrahydropyran, dioxane, piperazine, piperidine, piperazinone, piperidinone, pyran, thiomorpholine-S-oxide, thiomorpholine-S-dioxide, thiomorpholine, dihydrooxazine, morpholinedione, morpholinethione, perhydrothiazine dioxide,
- heteroaryl is understood as meaning stable five- or six-membered heterocyclic aromatics or 8- to 10-membered bicyclic heteroaryl rings which may contain one, two or three heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen in each ring and additionally contain as many conjugated double bonds that an aromatic system is formed.
- heterocyclic aromatic compounds are mentioned, but are not intended to be be limited:
- Oxadiazole triazole, tetrazole, furazane, thiadiazole, pyridine, pyrimidine, pyrazine, pyridazine,
- heteroaryls mentioned above may be substituted by one or more radicals selected from the group consisting of: (a) OH, NO 2 , CN, OCF 3 , OCHF 2 , OCH 2 F, NH 2 ,
- d- 6 alkyl preferably Ci -3 alkyl, more preferably ethyl, methyl, isopropyl or te / f-butyl,
- Bicyclic heteroaryl rings may preferably be substituted in the phenyl radical.
- halogen is understood as meaning fluorine, chlorine, bromine or iodine atoms.
- the application also includes the individual diastereomeric antipode pairs or mixtures thereof, which are present when more than one chirality element is present in the compounds of general formula I, as well as the individual optically active enantiomers which make up the racemates mentioned.
- the invention further provides a process for the preparation of the compounds of general formula I, wherein the substituents have the abovementioned meaning.
- the order of carrying out the reaction schemes can be varied to simplify the reactions or to prevent unwanted by-products.
- the following examples are named to illustrate the invention.
- the examples are intended to illustrate the invention and are not intended to limit the invention in any way.
- the final product can be further derivatized, eg by manipulation of the substituents. These manipulations may be those well known to those skilled in the art such as, but not limited to, oxidation, reduction, alkylation, acylation, and hydrolysis.
- the compounds of this invention may be prepared according to the illustrated schemes and specific examples or corresponding modifications thereof, using known and / or available starting materials, reagents and conventional synthetic methods. Of these reactions, it is also possible to use modifications which are known to a person skilled in the art but are not described in detail here.
- a compound of general formula I in which A, R 1 , R 2 and R 3 are as defined above and X is a linker of formula (He) can be prepared by coupling an amine of general formula (1-1) in which A, R 1 , R 2 , R 3 , R 4 and R 5 are defined as mentioned above, with a carboxylic acid of the general formula (1-2) in which R 3 is defined as mentioned above with the addition of common peptide coupling reagents and a base in an inert solvent (see, for example, Houben-Weyl, Methods of Organic Chemistry, Vol.
- the activation of the carboxyl group can alternatively also be carried out via the acid anhydride or acid chloride by methods which are known to the person skilled in the art.
- auxiliary bases for the coupling of the activated carboxyl function with a suitable amine for example triethylamine, ethyldiisopropylamine, morpholine or other tertiary amine bases can be used.
- the Cbz protecting group may be removed by standard methods known to those skilled in the art.
- the reaction is generally carried out in inert solvents, in the presence of a catalyst, preferably palladium on carbon, at room temperature in a hydrogen atmosphere under elevated pressure.
- a catalyst preferably palladium on carbon
- the activation of the carboxyl group takes place via a corresponding acid anhydride or acid chloride.
- the reaction is generally carried out in inert solvents in the presence of a base, preferably in a temperature range from room temperature to reflux of the solvent at atmospheric pressure.
- the reaction starts with an aromatic compound of the general formula (4-1) in which R 3 is defined as mentioned above, which under Friedel-Crafts conditions with a Succinic anhydride derivative of the general formula (4-2) in which R 4 and R 5 are defined as mentioned above, and a Lewis acid is reacted in an inert solvent.
- the reaction is preferably carried out in a temperature range from 0 ° C. to the reflux of the solvent under atmospheric pressure.
- the compounds of the general formula (7-3) in which R 1 and R 2 are defined as mentioned above can be hydrogenated with a catalyst and hydrogen in a temperature range from room temperature to reflux of the solvent at elevated pressure.
- Particularly preferred is the use of Raney nickel in ethanolic ammonia in a 3 bar hydrogen atmosphere at 50 0 C.
- Ethyl- (3-dimethylamino-propyl) -carbodiimide O- (1H-benzotriazol-1-yl) -N, NN, N-tetramethyl-uronium-hexa-fluorophosphate (HBTU) or tetrafluoroborate (TBTU) or 1 H-Benzotriazol-1-yl-oxy-tris (dimethylamino) phosphonium hexafluorophosphate (BOP).
- HBTU N-tetramethyl-uronium-hexa-fluorophosphate
- TBTU tetrafluoroborate
- BOP 1 H-Benzotriazol-1-yl-oxy-tris (dimethylamino) phosphonium hexafluorophosphate
- nitroaryl derivatives of the general formula (8-1) in which R 6 is as hereinbefore defined are with chlorophenoxyacetonitrile under Zuzz- would take a base in an inert solvent in a temperature range of -20 0 C to reflux of the solvent implemented. Most particularly preferred are reactions in DMF, potassium-te / f-butoxide as base at a temperature of -10 0 C under atmospheric pressure.
- the reduction of a nitrile of the general formula (8-2) in which R 6 is defined as mentioned above gives a corresponding amine of the general formula (8-3) in which R 6 is defined as mentioned above.
- Such reductions are known to the person skilled in the art.
- Particularly preferred is the use of 1 M borane in THF.
- the amino functionality can be alkylated by methods known to those skilled in the art. Particularly preferred are reductive aminations.
- An amine of the general formula (8-3) in which R 6 is defined as mentioned above reacts with a ketone of the general formula (8-8) in which R 2 is defined as mentioned above, in the presence of an acid and a reducing agent.
- the reaction is carried out in inert solvents, such as chlorinated hydrocarbons or ethers.
- Preferred solvents are dichloromethane, 1, 2-dichloroethane, diethyl ether, THF or mixtures thereof.
- Suitable acids are mineral acids such as acetic acid or hydrochloric acid, or organic acids such as p-toluenesulfone acid.
- novel compounds of general formula I according to the invention may contain one or more chiral centers. For example, if there are two chiral centers, then the compounds can be in the form of two diastereomeric antipode pairs.
- the invention includes the individual isomers as well as their mixtures. The separation of the respective diastereomers succeeds on the basis of their different physicochemical properties, for example by fractional crystallization from suitable solvents, by high-pressure liquid or column chromatography using chiral or preferably achiral stationary phases.
- the racemate of a compound of the general formula I is reacted with one of the abovementioned optically active acids or bases in an equimolar amount in a solvent and the resulting crystalline, diastereomeric, optically active salts are separated by utilizing their different solubilities.
- This reaction can be carried out in any kind of solvents as long as they have a sufficient difference in the solubility of the salts.
- methanol, ethanol or mixtures thereof, for example in the volume ratio 50:50, are used.
- each of the optically active salts is dissolved in water, carefully neutralized with a base such as sodium carbonate or potassium carbonate, or with a suitable acid, for example with dilute hydrochloric acid or aqueous methanesulfonic acid, thereby giving the corresponding free compound in the (+) - or ( -) - Form received.
- a base such as sodium carbonate or potassium carbonate
- a suitable acid for example with dilute hydrochloric acid or aqueous methanesulfonic acid
- SK-N-MC cells are cultured in "Dulbecco's modified Eagle Medium”. The medium of confluent cultures is removed. The cells are washed twice with PBS buffer (Gibco 041-04190 M), removed by addition of PBS buffer, mixed with 0.02% EDTA, and isolated by centrifugation. After resuspension in 20 ml Balanced Salts Solution [BSS (in mM): NaCl 120, KCl 5.4, NaHCO 3 16.2, MgSO 4 0.8, NaHPO 4 1.0, CaCl 2 1.8, D-glucose 5.5, HEPES 30, pH 7.40]. The cells are centrifuged twice at 100 xg and resuspended in BSS.
- BSS Balanced Salts Solution
- the cells are homogenized using an Ultra-Turrax and centrifuged for 10 minutes at 3000 xg. The supernatant is discarded and the pellet in Tris buffer (10 mM Tris, 50 mM NaCl, 5 mM MgCl 2 , 1 mM EDTA, pH 7.40), supplemented with 1% bovine serum albumin and 0.1%.
- the cAMP contents of the samples are determined by means of radioimmunoassay (Amersham) and the pA 2 values of antagonistic substances are determined graphically.
- the compounds of the invention show in the described in v / fr-o test model CGRP antagonistic properties in a dose range between 10 "12 to 10 " 5 M.
- the compounds according to the invention and their salts with physiologically tolerated acids are thus suitable for the acute and prophylactic treatment of headaches, in particular migraine, cluster headache and tension-type headaches.
- the compounds according to the invention also have a positive influence on the following diseases: non-insulin-dependent diabetes mellitus ("NIDDM”), cardiovascular diseases, morphine tolerance, Clostridium toxin-induced diarrheal diseases, skin disorders, especially thermal and radiation-related skin damage including sunburn, skin, prurigo, pruriginous toxidermias as well as severe itching, inflammatory diseases, eg inflammatory joint diseases (osteoarthritis, rheumatoid arthritis, neurogenic arthritis), generalized soft tissue rheumatism (fibromyalgia), neurogenic inflammations of the oral mucosa, inflammatory lung diseases, allergic rhinitis, asthma, COPD, diseases associated with excessive vasodilation and consequent reduced tissue perfusion, eg, shock and sep
- NIDDM non-insul
- the compounds according to the invention have a soothing effect on pain conditions in general.
- the symptoms of menopausal, caused by vasodilation and increased blood flow hot flushes of estrogen-deficient women and hormone-treated prostate cancer patients and castrates is influenced by the CGRP antagonists of the present application preventively and acutely therapeutically favored, this therapy approach is characterized by hormone substitution by side effect poverty.
- the compounds according to the invention are preferably suitable for the acute and prophylactic treatment of migraine and cluster headache, for the treatment of irritable bowel syndrome (IBS) and for the preventive and acute therapeutic treatment of hot flushes of estrogen-deficient women.
- IBS irritable bowel syndrome
- the dosage required to achieve a corresponding effect is expediently by intravenous or subcutaneous administration 0.0001 to 3 mg / kg body weight, preferably 0.01 to 1 mg / kg body weight, and by oral, nasal or inhalative administration 0.01 to 10 mg / kg body weight, preferably 0.1 to 10 mg / kg body weight, one to three times daily.
- CGRP antagonists or / and CGRP-release inhibitors are in addition to a conventional hormone substitution, it is recommended to reduce the dosages given above, the dosage then being 1/5 of the lower limits specified above up to 1/1 of the above may be upper limits.
- Another object of the invention is the use of the compounds according to the invention as valuable aids for the production and purification (affinity chromatography).
- radioactive labeling for example by tritiation of suitable precursors, for example by catalytic hydrogenation with trithium or replacement of halogen atoms by tritium, in RIA and ELISA assays and as diagnostic or analytical tools in neurotransmitter research.
- agents include antiemetics, prokinetics, neuroleptics, antidepressants, neurokinin antagonists, anticonvulsants, histamine H1 receptor antagonists, ⁇ -blockers, ⁇ -agonists and ⁇ -antagonists, ergot alkaloids, weak analgesics, nonsteroidal anti-inflammatory drugs, corticosteroids, calcium Antagonists, 5-HT 1B / i D agonists or other antimigraine agents, together with one or more inert customary carriers and / or diluents, for example corn starch, milk sugar, cane sugar, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, Water / ethanol, water / -
- the non-steroidal anti-inflammatory drugs aceclofenac, acemetacin, acetylsalicylic acid, acetaminophen (paracetamol), azathioprine, diclofenac, diflunisal, fenbufen, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, leflunomide, lornoxicam, mefenamic acid are thus used as further active substances , Naproxen, phenylbutazone, piroxicam, sulfasalazine, zomepirac or their pharmaceutically acceptable salts, as well as meloxicam and other selective COX2 inhibitors, such as rofecoxib, valdecoxib, parecoxib, etoricoxib and celecoxib, as well as substances which inhibit earlier or later steps in prostaglandin. Inhibit synthesis
- CGRP antagonists with vanilloid receptor antagonists e.g. VR-1 antagonists, glutamate receptor antagonists, e.g. mGlu5 receptor antagonists, mGlui receptor antagonists, iGlu5 receptor antagonists, AM-PA receptor antagonists, purine receptor blockers, e.g. P2X3 antagonists, NO synthase inhibitors, e.g. iNOS inhibitors, calcium channel blockers, e.g. PQ-type blockers, N-type blockers, potassium channel openers, e.g. KCNQ channel openers, sodium channel blockers, e.g. PN3 channel blockers, NMDA receptor antagonists, acid-sensing ion channel antagonists, e.g.
- bradykinin receptor antagonists such as e.g. B1 receptor antagonists, cannabinoid receptor agonists, e.g. CB2 agonists, CB1 agonists, somatostatin receptor agonists, e.g. sst2 receptor agonists are given.
- the dose for these active substances is expediently 1/5 of the usually recommended lowest dosage up to 1/1 of the normally recommended dosage, so for example 20 to 100 mg sumatriptan.
- the compounds according to the invention may be administered either alone or optionally in combination with other active substances for the treatment of migraine intravenously, subcutaneously, intramuscularly, intraarticularly, intrarectally, intranasally, by inhalation, topically, transdermally or orally, in particular aerosol formulations being suitable for inhalation.
- the combinations may be administered either simultaneously or sequentially.
- Suitable application forms are, for example, tablets, capsules, solutions, juices, emulsions or inhalable powders or aerosols.
- the proportion of the pharmaceutically active compound (s) in each case in the range of 0.1 to 90 wt .-%, preferably 0.5 to 50 wt .-% of the total composition, ie in amounts which are sufficient to reach the above-mentioned dosage range.
- Oral administration may be in the form of a tablet, as a powder, as a powder in a capsule (e.g., hard gelatin capsule), as a solution or suspension.
- the active substance combination can be carried out as a powder, as an aqueous or aqueous-ethanolic solution or by means of a propellant gas formulation.
- compositions are preferably characterized by the content of one or more compounds of the formula I according to the above preferred embodiments.
- Corresponding tablets can be prepared, for example, by mixing the active substance (s) with known excipients, for example inert diluents such as calcium carbonate, calcium phosphate or lactose, disintegrants such as corn starch or alginic acid, binders such as starch or gelatin, lubricants such as magnesium stearate or talc, and / or agents for achieving the depot effect, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate.
- the tablets can also consist of several layers.
- Juices of the active compounds or active compound combinations according to the invention may additionally contain a sweetening agent, such as saccharin, cyclamate, glycerol or sugar, and a taste-improving agent, for example flavorings, such as vanillin or orange extract.
- a sweetening agent such as saccharin, cyclamate, glycerol or sugar
- a taste-improving agent for example flavorings, such as vanillin or orange extract.
- the capsules containing one or more active ingredients or combinations of active substances can be prepared, for example, by mixing the active ingredients with inert carriers, such as lactose or sorbitol, and encapsulating them in gelatine capsules.
- suitable suppositories can be prepared, for example, by mixing with suitable carriers, such as neutral fats or polyethylene glycol or its derivatives.
- Adjuvants may include, for example, water, pharmaceutically acceptable organic solvents such as paraffins (e.g., petroleum fractions), oils of vegetable origin (e.g., peanut or sesame oil), mono- or polyfunctional alcohols (e.g., ethanol or glycerin), carriers such as e.g.
- pharmaceutically acceptable organic solvents such as paraffins (e.g., petroleum fractions), oils of vegetable origin (e.g., peanut or sesame oil), mono- or polyfunctional alcohols (e.g., ethanol or glycerin), carriers such as e.g.
- ground natural minerals eg kaolins, clays, talc, chalk
- ground synthetic minerals eg fumed silica and silicates
- sugars eg pipe, milk and dextrose
- emulsifiers eg lignin, liquors, methylcellulose, starch and polyvinylpyrrolidone
- lubricants eg Magnesium stearate, talc, stearic acid and sodium lauryl sulfate.
- propellant-free inhalable solutions also includes concentrates or sterile, ready-to-use inhalable solutions.
- the administration forms which can be used in the context of the present invention will be described in detail in the following part of the description.
- the ratios indicated for the flow agents relate to volume units of the respective solvents.
- the indicated volume units at NH 3 refer to a concentrated solution of NH 3 in water.
- the acid, base and salt solutions used in the workup of the reaction solutions are aqueous systems of the indicated concentrations.
- silica gel from Millipore MATREX TM, 35-70 ⁇ m is used.
- HPLC data are collected under the parameters listed below and using the listed columns:
- solvent A water (with 0.1% formic acid)
- Solvent B acetonitrile (with 0.1% NH 4 OH)
- Solvent A water (with 0.1% trifluoroacetic acid)
- Solvent B acetonitrile (with 0.1% trifluoroacetic acid)
- Preparative HPLC purifications generally use the same gradients used in the collection of analytical HPLC data.
- the collection of products is mass-controlled, the product-containing fractions are combined and freeze-dried.
- Step 3 (1-Benzyl-piperidin-4-yl) - [2- (5-methoxy-2-nitrophenyl) -ethyl-1-amine
- Step 1 ⁇ 2- [4- (7-Methoxy-2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidin-1-yl-1-2-oxo-ethyl) - -carbamic
- Step 2 3- [1- (2-Aminoacetyl) -piperidine-4-vH-7-methoxy-1,3-A5-tetrahydro-1,3-benzodiazepin-2-one
- Step 1 ⁇ 2-Oxo-2- [4- (2-oxo-1, 2 A5-tetrahydro-1, 3-benzodiazepin-3-yl) -piperidine-1 ⁇ yli-ethvD-carbamic acid benzyl ester
- Step 1 ⁇ 2-Oxo-2-r4- (2-oxo-2,3-dihydroimidazor4,5-olpyridin-1-yl) -piperidin-1-yl-ethyl) -carbamic acid benzyl ester
- Step 2 1 - [1- (2-Amino-acetyl) -piperidin-4-yl-1, 3-dihydroimidazo [4,5- ⁇ 1-pyridin-2-one
- Methanol was hydrogenated for 1 h at RT in a hydrogen atmosphere of 3 bar.
- Step 1 [4- (7-methoxy-2-oxo-1, 2, 4,5-tetrahydro-1, 3-benzodiazepin-3-yl) -piperidine-1 ⁇ yli-acetonitrile
- Step 1 4- (Cyclopropanecarbonyl-amino) -3-methyl-benzoic acid methyl ester
- Step 4 2-Cyclopropyl-7-methyl-1 / - / - benzimidazole-5-carboxylic acid methyl ester
- Step 5 2-Cyclopropyl-7-methyl-1 / - / - benzimidazole-5-carboxylic acid
- Step 2 4-Methyl-2-oxo-2,3-dihydro-benzoxazole-6-carboxylic acid
- Step 1 7-Methyl-2-oxo-2,3-dihydro-1 / - / - benzimidazole-5-carboxylic acid methyl ester
- Step 2 7-Methyl-2-oxo-2,3-dihydro-1 / - / - benzimidazole-5-carboxylic acid
- Step 1 7-Methyl-1 / - / - benzotriazole-5-carboxylic acid methyl ester
- Step 1 7-Methyl-3 / - / - benzimidazole-5-carboxylic acid methyl ester
- Step 2 7-Methyl-3 / - / - benzimidazole-5-carboxylic acid
- Step 1 3-Chloro-5- (2-ethyl-piperidine-1-carbonyl) -benzoic acid methyl ester
- Step 1 4-Methyl-2-oxo-2,3-dihydro-benzooxazole-6-carboxylic acid benzyl ester
- Step 2 Benzyl 3,4-dimethyl-2-oxo-2,3-dihydro-benzooxazole-6-carboxylate
- Step 2 4- (7-Bromo-2-cavanamino-1H-benzimidazol-5-yl) -4-oxo-butyric acid methyl ester and 4- (7-bromo-2-ureido-1 / - / - benzimidazole-5- yl) -4-oxo-butyric acid methyl ester
- Step 3 4- (7-Bromo-2-covanoamino-1 / - / - benzimidazol-5-yl) -4-oxo-butyric acid and 4- (7-bromo-2-ureido-1 / - / - benzimidazole-5 yl) -4-oxo-butyric acid
- Step 1 4- (3-Acetylamino-2,4-dimethylphenyl) -4-oxo-butyric acid
- Step 2 4- (3-Amino-2,4-dimethylphenyl) -4-oxo-butyric acid hydrochloride
- Step 1 4- (4-Methyl-2-oxo-2,3-dihydro-benzooxazol-6-yl) -4-oxo-butyric acid methyl ester
- Step 1 4- (7-bromo-2-oxo-1, 2, 4,5-tetrahydro-1, 3-benzodiazepin-3-yl) -piperidine-1 ⁇ carboxylic acid fe / f-butyl ester
- the batch was cooled, filtered through a frit and concentrated by rotary evaporation.
- the residue was stirred in 10 ml of DCM with the addition of 2.0 ml of trifluoroacetic acid at RT overnight.
- the mixture was i.vac. concentrated and the remaining residue stirred with diethyl ether.
- the precipitated as a solid product was filtered off with suction and i.vac. dried.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne de nouveaux antagonistes du CGRP représentés par la formule générale (I), dans laquelle A, X, R1, R2 et R3 sont tels que définis dans la description, leurs tautomères, leurs isomères, leurs diastéréoisomères leurs énantiomères, leurs hydrates, leurs mélanges, et leurs sels, ainsi que les hydrates des sels, en particulier, leurs sels physiologiquement acceptables comprenant des acides ou des bases inorganiques ou organiques, des médicaments contenant ces composés, leur utilisation et leur procédé de production.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07115904.0 | 2007-09-07 | ||
EP07115904 | 2007-09-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009034029A2 true WO2009034029A2 (fr) | 2009-03-19 |
WO2009034029A3 WO2009034029A3 (fr) | 2009-07-09 |
Family
ID=39205275
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2008/061771 WO2009034029A2 (fr) | 2007-09-07 | 2008-09-05 | Nouveaux composés |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2009034029A2 (fr) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8450327B2 (en) | 2007-10-18 | 2013-05-28 | Boehringer Ingelheim International Gmbh | CGRP antagonists |
US8629137B2 (en) | 2007-10-18 | 2014-01-14 | Boehringer Ingelheim International Gmbh | CGRP antagonists |
US8829006B2 (en) | 2007-11-22 | 2014-09-09 | Boehringer Ingelheim International Gmbh | Compounds |
JP2016531942A (ja) * | 2013-09-26 | 2016-10-13 | シーエイチディーアイ ファウンデーション,インコーポレーテッド | キヌレニン−3−モノオキシゲナーゼ阻害薬、医薬組成物、及びこれらの使用方法 |
EP3130583A1 (fr) * | 2012-04-05 | 2017-02-15 | CHDI Foundation, Inc. | Inhibiteurs de kynurenine-3-monooxygenase, compositions pharmaceutiques et leurs procédés d'utilisation |
US9884853B2 (en) * | 2013-09-26 | 2018-02-06 | Chdi Foundation, Inc. | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
CN112624979A (zh) * | 2019-10-09 | 2021-04-09 | 浙江瑞博制药有限公司 | 一种苯并咪唑化合物的制备方法 |
US11400081B2 (en) | 2017-05-17 | 2022-08-02 | The University Of Sheffield | Compounds |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK131147B (da) * | 1969-10-27 | 1975-06-02 | Sumitomo Chemical Co | Fremgangsmåde til fremstilling af butyrophenonderivater eller syreadditionssalte deraf. |
PH17194A (en) * | 1980-03-06 | 1984-06-19 | Otsuka Pharma Co Ltd | Novel carbostyril derivatives,and pharmaceutical composition containing the same |
DE19952147A1 (de) * | 1999-10-29 | 2001-05-03 | Boehringer Ingelheim Pharma | Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
DE19952146A1 (de) * | 1999-10-29 | 2001-06-07 | Boehringer Ingelheim Pharma | Arylalkane, Arylalkene und Aryl-azaalkane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
-
2008
- 2008-09-05 WO PCT/EP2008/061771 patent/WO2009034029A2/fr active Application Filing
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8450327B2 (en) | 2007-10-18 | 2013-05-28 | Boehringer Ingelheim International Gmbh | CGRP antagonists |
US8629137B2 (en) | 2007-10-18 | 2014-01-14 | Boehringer Ingelheim International Gmbh | CGRP antagonists |
US8829006B2 (en) | 2007-11-22 | 2014-09-09 | Boehringer Ingelheim International Gmbh | Compounds |
JP2018108997A (ja) * | 2012-04-05 | 2018-07-12 | シーエイチディーアイ ファウンデーション,インコーポレーテッド | キヌレニン−3−モノオキシゲナーゼインヒビターおよびその医薬組成物ならびにこれらの使用方法 |
EP3130583A1 (fr) * | 2012-04-05 | 2017-02-15 | CHDI Foundation, Inc. | Inhibiteurs de kynurenine-3-monooxygenase, compositions pharmaceutiques et leurs procédés d'utilisation |
US9822058B2 (en) | 2012-04-05 | 2017-11-21 | Chdi Foundation, Inc. | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
US10442782B2 (en) * | 2012-04-05 | 2019-10-15 | Chdi Foundation, Inc. | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
EP3049389A4 (fr) * | 2013-09-26 | 2017-04-19 | CHDI Foundation, Inc. | Inhibiteurs de kynurénine-3-monooxygénase, compositions pharmaceutiques et procédés d'utilisation de ceux-ci |
US9884853B2 (en) * | 2013-09-26 | 2018-02-06 | Chdi Foundation, Inc. | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
US9938252B2 (en) | 2013-09-26 | 2018-04-10 | Chdi Foundation, Inc. | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
JP2016531942A (ja) * | 2013-09-26 | 2016-10-13 | シーエイチディーアイ ファウンデーション,インコーポレーテッド | キヌレニン−3−モノオキシゲナーゼ阻害薬、医薬組成物、及びこれらの使用方法 |
US10428054B2 (en) | 2013-09-26 | 2019-10-01 | Chdi Foundation, Inc. | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
US10501433B2 (en) | 2013-09-26 | 2019-12-10 | Chdi Foundation, Inc. | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
US11400081B2 (en) | 2017-05-17 | 2022-08-02 | The University Of Sheffield | Compounds |
CN112624979A (zh) * | 2019-10-09 | 2021-04-09 | 浙江瑞博制药有限公司 | 一种苯并咪唑化合物的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2009034029A3 (fr) | 2009-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1487821B1 (fr) | Piperidines substituees par benzodiazepine a utiliser dans le traitement de maladies cardiovasculaires | |
EP2225237A2 (fr) | Composés organiques | |
WO2009050232A1 (fr) | Antagonistes du cgrp | |
EP2062889A1 (fr) | Composés | |
WO2009034029A2 (fr) | Nouveaux composés | |
EP2438067B1 (fr) | Spirolactames comme antagonistes du cgrp | |
EP2205599B1 (fr) | Antagonistes du cgrp | |
EP2225223A2 (fr) | Composés organiques | |
WO2001032649A1 (fr) | Arylalcane, arylalcene et aryl-aza-alcane, medicaments renfermant ces composes et leur procede de preparation | |
MXPA04010702A (es) | Moduladores tetrahidropiranil-ciclopentil-tetrahidropiridopiridinicos de la actividad de receptores de quimiocina. | |
WO2007045672A1 (fr) | Antagonistes de cgrp selectionnes, leur procede de production et leur utilisation en tant que medicament | |
WO2000008014A1 (fr) | Heterocycles bicycliques disubstitues, en particulier a effet inhibiteur de la thrombine | |
EP2225236A2 (fr) | Composés organiques | |
EP2379529B1 (fr) | Antagonistes du cgrp | |
EP1992349B1 (fr) | Antagonistes CGRP, leur préparation et leur utilisation comme médicament | |
DE102005050953A1 (de) | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel | |
WO2009034028A2 (fr) | Nouveaux composés | |
WO2009050235A1 (fr) | Antagonistes du cgrp | |
WO2009050237A1 (fr) | Antagonistes du cgrp |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08803740 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08803740 Country of ref document: EP Kind code of ref document: A2 |